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Summary
An improved purification of xanthine oxidoreductase (XOR) is described, 
where yields of 20-30 mg of pure enzyme can be obtained per litre of 
frozen breast milk. The kinetic and physicochemical properties of purified 
human XOR were compared with those of the bovine milk enzyme, 
similarly prepared.
The low enzymic activity of human XOR towards xanthine and related 
substrates was confirmed and explained on the basis of a high proportion 
(>95%) of demolybdo enzyme. The deficit of molybdenum was associated 
with a lack of molybdenum cofactor and with a 30% loss of iron-sulphur 
centres. Of the low content of molybdenum-containing enzyme, 
approximately 60% was shown, on the basis of activity and resulphuration 
experiments, to consist of desulpho enzyme. The substrate specificity of 
human milk XOR was closer to that of human liver enzyme than to that of 
bovine milk XOR.
Human milk XOR showed several physicochemical differences from the 
bovine enzyme, notably a consistently higher apparent molecular weight, 
greater tendency to aggregate and higher affinity for heparin. Moreover 
the conversion of dehydrogenase to oxidase form was less complete than 
for bovine milk XOR.
The NADH oxidase activity of human milk XOR was investigated and a 
speculative recycling mechanism is proposed whereby, in the presence of 
NAD+, the dehydrogenase form of XOR can generate significant amounts 
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2 Aims
Although mammalian XOR from bovine milk and rat liver has been well 
characterised, relatively little is known about the human enzyme. The 
aims of the present work were to develop an improved purification 
procedure from human milk and to compare the kinetic and 
physicochemical properties of the purified human enzyme with those of 
the enzyme from bovine milk. By these means, it was hoped to clarify the 
molecular bases and physiological relevance of differences between the 
enzyme from human milk and those from other mammalian species.
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3 Materials and Methods
3.1 Materials
3.1.1 Chemicals
Bovine Milk Xanthine Oxidoreductase was obtained from Biozyme, 
Blaenavon, Gwent. “Protogel” (Acrylamide-bisacrylamide stock solution) 
was obtained from National Diagnostics, Atlanta, Georgia, USA. Bio-rad 
protein assay reagent concentrate was obtained from Bio-rad, Hemel 
Hempstead, Hertfordshire. Dimercaptotoluene was obtained from Fluka, 
Gillingham, Dorset. All other chemicals were obtained from Sigma-Aldrich, 
Poole, Dorset; BDH, Poole, Dorset; and Fisher Scientific, Loughborough, 
Leicestershire.
3.1.2 Column chromatography
AH Sepharose, Mono Q Hi-trap columns, Hi Load 16/60 Prep Grade 
Superdex 200 gel filtration column and Sephadex G25 PD10 buffer 
exchange columns were obtained from Pharmacia, Uppsala, Sweden. 
Heparin-agarose (Type I) was obtained from Sigma, Poole, Dorset. 
Syringe Filters were obtained from Whatman, Maidstone, Kent.
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3.1.3 Equipment
PAGE was carried out using either the Protean II or Mini-Protean II 
electrophoresis tanks and plates, obtained from Biorad, Hemel 
Hempstead, Hertfordshire. Column chromatography was performed using 
a Pharmacia FPLC system from Pharmacia, Uppsala, Sweden. HPLC was 
carried out on a Waters HPLC system equipped with a Waters 
multiwavelength detector from Waters chromatography division, Millipore 
corporation, Massachusetts.
3.1.4 Instruments
Spectrophotometric assays were performed using either a Cecil CE 6600 
Multimode Computing UV Spectrophotometer or a Cecil CE 272 linear 
readout UV Spectrophotometer. Spectra were taken using a Cecil CE 
6600 Multimode Computing UV Spectrophotometer. Fluorimetric assays 
were done using a Perkin-Elmer LS-5B Luminescence Spectrometer. 
Dynamic light scattering studies were performed using an Oros 




3.2.1 Dye binding protein estimation
Protein estimations were done according to the method of Bradford 
(1976). Commercially-available BMXOR or BSA were used as the 
standard for estimations of protein in solutions of pure enzyme or crude 
extracts respectively. The standard, diluted to a range of concentrations 
from 0 to 100 pg/ml, and unknown samples at appropriate dilutions (100 
pi) were added to BIO-RAD protein assay reagent (0.9 ml) in a 1 ml 
plastic cuvette, mixed by inversion and left for 10 min to allow colour 
development. The absorbance at 595 nm was determined and protein 
concentration was calculated from a linear standard curve.
3.2.2 Calculation of XOR concentration from spectra
XOR concentration was calculated from the A450 using extinction 
coefficients estimated in Section 7.3.1. If no extinction coefficient had 
been estimated, an e of 36000 M'1 cm'1 was used, which assumes fully 
functional enzyme (Bray, 1975).
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3.2.3 Xanthine oxidase activity assay
The total xanthine oxidase activity was determined by measuring the rate 
of oxidation of xanthine to uric acid spectrophotometrically at 295 nm, 
using an absorption coefficient of 9600 M'1 cm'1 (Avis et al., 1956 a). 
Assays were performed in acrylic cuvettes (1 ml) at 25°C in air-saturated 
50 mM Na-Bicine, pH 8.3, unless otherwise stated, containing 100pM 
xanthine and 500pM NAD+.
3.2.4 Oxidase content
The oxidase content was determined by measuring the rate of oxidation of 
xanthine to uric acid spectrophotometrically, as described in Section 
3.2.3, at 25°C in air-saturated 50 mM Na-Bicine, pH 8.3, containing 
100pM xanthine in the absence of 500pM NAD+. Percentage oxidase was 
calculated by dividing the rate in the absence of NAD+ which was 
assumed to be the oxidase, by that in the presence of NAD+, which was 
assumed to be the sum of the oxidase and dehydrogenase. This fraction 
was expressed as a percentage.
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3.2.5 NADH oxidase assays
NADH oxidase activity was determined by measuring the rate of oxidation 
of NADH to NAD+ spectrophotometrically at 340 nm, using an absorption 
coefficient of 6220 M'1 cm'1 for NADH (Horecker & Kornberg, 1948). 
Assays were performed in acrylic cuvettes at 25°C in air-saturated 50 mM 
Na-Bicine, pH 8.3, unless otherwise stated, containing 100 pM NADH.
3.2.6 Fluorescence assay for xanthine oxidase activity
The more sensitive fluorescence assay of Beckman et al. (1989) was 
used when there was too little activity to be measured using the standard 
spectroscopic assay or when turbidity of the solution made the 
spectroscopic assay unfeasible. The assay utilises the conversion of 
pterin by XOR to the fluorescent product, isoxanthopterin. Pterin is 
oxidised to isoxanthopterin at the molybdenum site by the same 
mechanism that oxidises xanthine to urate.
Assays were carried out in a Perkin-Elmer LS-5B Luminescence 
Spectrometer at room temperature, with an excitation wavelength of 
345 nm and emission wavelength of 390 nm. Sample (10 pi), was added 
to 50 mM potassium phosphate, pH 7.4, (970 pi) in 1 ml quartz fluorimeter 
cells and fluorescence monitored to ensure a stable baseline. Pterin
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(1 mM stock solution, 10 pi) was added, mixed by inversion and 
fluorescence monitored to give the oxidase activity. Methylene blue (1 mM 
stock solution, 10 pi) was added, mixed by inversion and fluorescence 
monitored to give the total activity (XO+XDH). Allopurinol (4 mM stock 
solution, 1 O j l iI )  was added, mixed by inversion and fluorescence was 
monitored to confirm that the production of fluorescent product was 
allopurinol-inhibitible. This also allows calibration by adding known 
amounts of isoxanthopterin, which act as an internal standard and takes 
into account the differences observed in fluorescence quenching and light 
scatter.
3.2.7 Calculation of AFR
AFR [Activity (units/l) / A450] is a convenient method to describe the 
functionality of an XOR sample (Avis et a/., 1955). AFR is calculated by 
dividing the rate of increase of A295 (AU/min) of the assay described in 
Section 3.2.3 by the A450 of sample as diluted in the assay. An AFR value 
of 210 has become accepted to indicative of 100% functional enzyme 
(Massey et a/., 1970).
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3.2.8 Calculation of PFR
PFR (A28o / A450) is a convenient method to describe the purity of an XOR 
sample (Avis et al.f 1955). PFR is calculated by dividing A28o by the A450 of 
the sample. A PFR value of 5 has become accepted as representative of 
highly pure XOR.
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4 Purification of Human and Bovine Milk Xanthine
Oxidase
4.1 Introduction
The purification of xanthine oxidoreductase (XOR) from bovine milk was 
first reported in 1924 by Dixon & Thurlow, and in 1939, separately Ball 
and Corran et al. obtained enzyme of sufficient purity to show the 
presence of flavin and the possibility of another chromophore in the 
visible spectrum. By 1955, Avis et al. had developed a purification 
procedure which yielded crystalline XOR with a protein (280 nm) to flavin 
(450 nm) ratio (PFR) of 5.0-5.2, which later became accepted as 
indicative of a very high level of purity. Subsequently, XOR has been 
purified from a wide variety of species and sources. The early purification 
procedures were relatively harsh by current standards, involving solvent 
extraction, drying, acid and heat treatment and exposure to proteases 
(Massey & Harris, 1997).
Bovine milk has most commonly been used as a source of XOR as it 
contains relatively high amounts of the enzyme, with fewer contaminating 
proteins than do other tissue sources. The procedure used by Avis et al. 
(1955), yielding XOR of high purity, required the proteolysis, using 
pancreatin, of buttermilk. Proteolysis was found to selectively denature
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and precipitate contaminating casein and has also been implicated in the 
release the enzyme from the milk fat globule membrane (Briley & 
Eisenthal, 1974). The widespread use of proteases delayed the 
identification of the dehydrogenase form of XOR (XDH) until 1969 when 
Stirpe & Della Corte described an apparent activation of rat liver XOR in 
the presence of proteases and established the phenomenon of protease- 
induced irreversible XDH to XO conversion (See General Introduction).
Many different chromatographic methods have been employed in the 
purification of XOR. Calcium phosphate chromatography generally gives a 
large increase in purity with little loss of total activity (Avis et al., 1955) 
and has been used successfully in preparations of XOR from a wide 
variety of sources. However, in the experience of our laboratory, 
inconsistency in binding capacity between batches and short effective life 
make this material unreliable. An important advance involved the use of 
folate as an affinity ligand (Nishino et al., 1981). Folate, which can be 
covalently bound to Sepharose, is a competitive inhibitor of XO with a Kj 
of 42 pM (Nishino & Tsushima, 1986), convenient for use as an affinity 
ligand. Folate has the particular advantage that it only binds to molybdo 
(molybdenum-containing) enzyme so facilitating the fractionation of active 
and inactive forms which occur in most preparations (See General 
Introduction and Chapter 10).
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There are few reports of the purification of XOR from human sources. 
Human milk was long thought to contain very little XOR, because of the 
low enzymic activity towards xanthine in this tissue. Zikakis et al. (1983) 
described a preparation of highly impure enzyme, obtained by a 
combination of mild non-ionic detergent and multiple chromatographic 
techniques. Six years later, Graham et al. (1989) briefly reported a purer 
product using salt precipitation followed by hydroxy lapatite
chromatography. Krenitsky et al. (1986) reported purification of a highly 
proteolysed enzyme from post-mortem human liver using batchwise 
calcium phosphate chromatography followed by the use of a novel affinity 
ligand, 9-(p-amino-ethoxyphenyl) guanine coupled to Sepharose 4B.
Abadeh et al. in 1992 described a preparation from human milk of 
relatively pure XOR. Their procedure was based on that of Nakamura & 
Yamazaki (1982) for bovine milk and involved the use of a high ionic 
strength buffer to liberate XOR from the cream and ammonium sulphate 
precipitation followed by calcium phosphate chromatography. This 
procedure has subsequently been modified in our laboratory, most 
recently resulting in that described by Sanders et al. (1997). In this 
preparative method, calcium phosphate chromatography is replaced by 
heparin chromatography; an advance based on findings of Adachi et al. 
(1993) who in the course of studies on the binding of XOR to cell 
surfaces, demonstrated binding of HMXOR to heparin. Although the
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application of heparin binding in purification procedures was not 
suggested by these workers, the potential was clearly evident. XOR binds 
to heparin, a sulphated glycosaminoglycan, via lysine and arginine rich 
peptides (Fukushima et a/.,1995).
4.2 Materials and Methods
4.2.1 Materials
Frozen human milk was kindly donated by mothers in the Special Care 
Baby Units of the Royal United Hospitals, Bath, Southmead Hospital, 
Bristol; Bristol Royal Infirmary and Princess Margaret Hospital, Swindon. 
Fresh human milk was kindly provided by mothers in the Bath and 
Chippenham Area. Fresh bovine milk was obtained from a local dairy herd 
in Claverton, Bath.
4.2.2 Purification of BMXOR and HMXOR according to Sanders et al. 
(1997).
To fresh, or thawed frozen milk, 1 mM EDTA and 0.1 mM phenylmethyl- 
sulphonyl fluoride (PMSF) were added, and the mixture was stirred for 20 
min before centrifuging (3000g, 30 min) at 4°C. All subsequent operations 
were carried out at 4°C. The cream was resuspended (50% v/v) in 0.2 M
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K2HP04 containing 1 mM EDTA and 0.1 mM PMSF, with stirring for 20 
min. The suspension was centrifuged (3000g, 30 min) and the aqueous 
supernatant was collected, filtered through glass wool and mixed with 
15% (v/v) butan-1-ol. 15% (w/v) Ammonium sulphate was added slowly 
and left stirring for 1 h before centrifuging (3000g, 20 min) and filtering the 
subnatant through glass wool. A further 20% (w/v) ammonium sulphate 
was added and allowed to stir for 45 min before centrifuging (3000g, 30 
min). The precipitate was resuspended in heparin chromatography buffer 
(H-buffer) (20 ml) (25 mM sodium-phosphate, pH 7.4, for HMXO and 25 
mM MES, pH 6.0, for BMXO containing 1 mM EDTA and 0.1 mM PMSF) 
and dialysed against the same buffer overnight. Any remaining precipitate 
was removed by centrifugation (27000g, 1 h) followed by filtration through 
a 0.22 pm filter, to yield a crude enzyme preparation.
A heparin column was prepared by packing heparin immobilised on 
cyanogen bromide-activated 4% cross-linked agarose in H-buffer into a 
column (1 cm x 6 cm) under gravity. The column was washed with H- 
buffer containing 1 M NaCI and equilibrated with H-buffer (20 ml) prior to 
use. The crude enzyme preparation, in H-buffer, was applied to the 
column at a flow rate of 20 ml/h. The column was washed with H-buffer 
(20 ml), containing 0.1 M NaCI and the enzyme was then eluted in H- 
buffer containing 0.4 M NaCI for HMXOR and 0.25 M NaCI for BMXOR.
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Further purification could be effected by using Mono Q anion exchange 
chromatography. XOR in 50 mM Na-Bicine buffer, pH 8.3, containing 50 
mM NaCI was filtered through a 0.22 p,m syringe filter and applied to an 
equilibrated 1ml Hi-Trap Mono Q ion exchange column (Pharmacia) at a 
flow rate of 1 ml/min. The column was eluted by a gradient of increasing 
salt concentration from 0.05 M to 0.5 M NaCI in 50 mM Na-Bicine buffer, 
pH 8.3, over 30 min. Fractions were collected and those containing the 
enzyme were pooled.
4.2.3 Folate Affinity Chromatography
Folate column preparation is that of Nishino et ai (1981) with slight 
modification. To swollen and washed (0.5M NaCI) AH Sepharose 4B 
(Pharmacia) (4 g dry weight) 2 mM folic acid in 50% dimethylformamide, 
pH 5.8, (30 ml) and 1-ethyl-3-(3-dimethylpropyl) carbodi-imide (200 mg) 
was added and the slurry was gently agitated at room temperature for 3 h 
or until the supernatant was not visibly yellow. This coupling procedure 
was repeated 3 times until the supernatant remained yellow. The gel was 
then washed sequentially with 50% DMF, 10 mM NaOH and 0.1M 
pyrophosphate buffer pH 8.5. The gel was packed into a column (1 cm x 6 
cm) which was covered with aluminium foil to exclude light, washed and 
stored at 4°C in 0.1 M pyrophosphate buffer, pH 8.5, until use.
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The folate Sepharose column was equilibrated in Buffer A [20% (v/v) 0.1 
M sodium pyrophosphate, pH 8.5, containing 0.2 mM EDTA and 80% (v/v) 
50 mM Tris-HCI, pH 7.8, containing 0.2 mM EDTA] before use. BMXOR in 
Buffer A was applied to the column at a flow rate of 0.5 ml/min until the 
column was visibly brown approximately one third of the way down. The 
column was then washed in Buffer A followed by Buffer B [30% (v/v) 0.1 M 
sodium pyrophosphate, pH 8.5, containing 0.2 mM EDTA and 70% (v/v) 
50 mM Tris-HCI, pH 7.8, containing 0.2 mM EDTA] until the UV 
absorbance had returned to baseline, at which time Buffer B, containing 
100 mM hypoxanthine was used to elute molybdo XOR.
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4.3 Results
4.3.1 Xanthine Oxidase Purification
HMXOR was initially purified from frozen human breast milk (1 I) using the 
procedure of Sanders et al. (1997), as described in Section 4.2.1, up to 
and including heparin chromatography. Using this procedure 5 mg 
HMXOR was obtained with PFR 5.1 - 5.5 and containing approximately 
70% oxidase activity (Table 4.1). A typical elution profile of HMXOR from 














Milk 1000 1180 17880 66 100
Resuspended
Cream
267 611 2008 305 52
K2HP04 wash 240 444 432 1028 38
1st (NH4)2S04 
subnatant
240 398 192 2075 34
Purified XOR 3 120 5 24784 10
Table 4.1. Purification of HMXOR using the procedure of Sanders et 
al. (1997) (Section 4.2.2). Protein concentrations and pterin oxidase 
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Elution Volume (ml)
F ig u re  4 .1 . E lu tio n  p ro file  o f c ru d e  H M X O R  fro m  a h e p a rin  a g a ro s e  
c o lu m n . The column eluate was monitored using a UV detector, linked to 
a chart recorder.
4 .3 .2  E ffe c t o f D T T  on th e  P u rific a tio n  o f  H M X O R
The effects of DTT on the early stages of purification of HMXOR were 
investigated by following the sequence of operations outlined in Fig. 4.2. 
Enzymic activity of Fractions 2 to 6 are shown in parentheses as 
percentages of the total starting activity shown as 100% in Fraction 1. 
Comparison of Fraction 2 vs. Fraction 3, also of Fraction 5 vs. Fraction 6, 
shows clearly that addition of DTT leads to greatly increased release of 
XOR from the cream. A second very important point emerges from this 
experiment. This is that initial stirring of thawed milk, prior to 
centrifugation, leads to extensive loss of XOR into the subnatant (Fraction
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3). It was, accordingly, decided to modify the preparation of Sanders et al. 
by centrifuging milk immediately after thawing (avoiding stirring) and to 
include DTT in the subsequent stirred washing of separated cream.
Thawed Human Breast Milk (100%) 
(Fraction 1)
+10mM DTT
Stirred at 4°C for 30 min 






Cream Subnatant (65%) 
(Fraction 3)
Stirred at 4°C for 1 h 
in 0.2 M K2HP04 
Centrifuged (3000g 10 min )
Cream Subnatant (17%) 
(Fraction 4 )
+10mM DTT
Stirred at 4°C for 1 h 
in 0.2 M K2H P O 4 
Centrifuged (3000g 10 min )
Cream Subnatant (41%) Cream Subnatant (15%) 
(Fraction 5) (Fraction 6)
Figure 4.2. Schematic diagram of the procedures used to monitor the 
effect of DTT on the purification of HMXOR. Pterin oxidase activity was 
determined as described in Section 3.2.6 and expressed as percentages 
of the total starting activity of Fraction 1.
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4.3.3 Improved Xanthine Oxidase Purification
In view of the results outlined in Section 4.3.2, the preparation of Sanders 
et al. (1997), was modified. Milk was centrifuged immediately after 
thawing and 10 mM DTT was added to the buffer used to resuspend the 
cream and maintained in all subsequent operations. Table 4.2 shows the 
purification details for HMXOR. It is noteworthy that the total enzyme 
activity of HMXOR increases following initial DTT treatment; an 
observation that will be discussed later. The improved purification 














Milk 1000 1230 17400 71 100
Resuspended
Cream
288 1281 1381 927 104
K2HP04 wash 213 1661 618 2690 135
1st (NH4)2S04 
subnatant
237 1235 190 6500 100
Purified XOR 5 554 21 26829 45
Table 4.2. Purification of HMXOR using the modified procedure 
(Section 4.3.3). Protein content and enzyme activity were determined as 












Milk 1000 27800 26400 1053 100
Resuspended
Cream
235 20728 1009 2535 75
K2HP04 wash 162 13492 518 26031 49
1st(NH4)2S04
subnatant
164 11502 279 41176 41
Purified XOR 4 4463 24 186417 16
Table 4.3. Purification of BMXOR using the modified procedure 
(Section 4.3.3). Protein content and enzyme activity were determined as 
described in the legend to Table 4.1.
4.3.4 Further Purification Using Mono Q Ion Exchange
Preparations of XOR after heparin chromatography often showed a 
contaminating band at 70 kDa on SDS-PAGE and a PFR above 5. Further 
purification by anion exchange chromatography used by Sanders et al. 
was re-examined. Preliminary experiments established that there was little 
difference between the binding and elution of HMXO over a range of pH 
from 8 to 9. Na-Bicine, pH 8.3, containing 0.05 M NaCI was chosen for 
Mono Q anion chromatography with a linear elution gradient of NaCI from 
0.05 M to 0.5 M, with a step at 0.2 M NaCI, in Na-Bicine, pH 8.3, over 30 
ml. Figure 4.3 shows a typical elution profile of HMXOR from Mono Q.
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After Mono Q chromatography HMXOR typically had a PFR of 5 to 5.1. If 
it is assumed that pure enzyme has a PFR of 5 (Bray, 1975), this 
corresponds to a purity of 98% to 100%, which is further validated by the 
enzyme running as a single band on SDS PAGE.
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Figure 4.3 Elution profile of HMXOR from a Hi-Trap Mono-Q column.
The column eluate was monitored using a UV detector, linked to a chart 




Folate chromatography was carried out to enrich BMXOR in molybdo 
enzyme and to provide some samples of low molybdenum content for 
comparative study with HMXOR. On all samples studied, two successive 
chromatography steps were carried out. The first affinity chromatography 
step (Figure 4.4) shows that unbound enzyme has a low AFR, but, as the 
column is washed, the AFR progressively increases. Upon elution with 
hypoxanthine, most of the XOR active fraction elutes. However the last 
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Figure 4.4. Elution Profile of BMXOR from a folate Sepharose 
column. Fractions were collected, and for each, the absorbance at 450nm 
was measured (□ ) and the AFR (O) was determined as described in 
Section 3.2.7.
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fact that desulpho XOR, which binds folate may have either a lower 
affinity for hypoxanthine or a higher affinity for folate than active XOR.
The second folate affinity chromatography step (Figure 4.5) shows that 
enzyme that doesn’t bind has a very low AFR and during the 
hypoxanthine elution the AFR increases, approaching that for 100% 
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Figure 4.5. Elution Profile of demolybdo-enriched BMXOR from a 
folate Sepharose column. Fractions were collected, and for each, the 
absorbance at 450nm was measured (□ ) and the AFR (O) was 
determined as described in Section 3.2.7.
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The specific activities of the enriched molybdo and demolybdo BMXOR 
fractions for xanthine and NADH oxidation were assayed (Table 4.4), 
demonstrating dramatic differences in the molybdenum-dependant 
xanthine activity and similar NADH oxidase activities.
Xanthine Oxidase Activity 
(nmol min'1 mg'1)
NADH Oxidase Activity 
(nmol min'1 mg'1)
Molybdo BMXOR 1538 ± 0 48 + 1
Demolybdo BMXOR 61 ±2 45 ± 2
Table 4.4 Xanthine and NADH oxidase activities of molybdo- and 
demolybdo-BMXOR. Enzyme concentration, xanthine oxidase activity 
and NADH oxidase activity were determined in air-saturated 50 mM Na- 




Using the procedure of Sanders et al. (1997), frozen human milk only 
yielded approximately 5 mg XOR protein per I milk. In attempts to prepare 
XOR in the dehydrogenase form (XDH), DTT was included in all buffers 
and, although overall yields remained similar to those obtained in the 
absence of DTT, it was observed that DTT facilitated the release of 
enzyme from the cream. This effect was confirmed in experiments outlined 
in Fig. 4.2. These experiments also highlighted the fact that initial stirring 
of thawed milk prior to the first centrifugation step led to considerable loss 
of enzyme activity from the cream. In the light of the above findings, the 
preparation of Sanders et al. was modified in two major ways. Firstly, 
frozen human milk was thawed and immediately centrifuged to obtain 
cream without previous stirring. Secondly, DTT was included in the 
subsequent washing step to maximise release of enzyme from the cream. 
As a consequence, HMXOR of undiminished purity was obtained at 
approximately four times the previous yield.
It is of interest that, in previous years, the preparation of Sanders et al. 
has always given much higher yields of BMXOR than of HMXOR. In 
retrospect, this may well have been a consequence of the use of fresh 
bovine milk, in contrast to frozen human milk routinely employed. The 
logistics of human milk collection largely dictate the use of frozen milk,
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which after thawing, is likely to have suffered disruption of the membrane 
surrounding the fat globules and to contain HMXOR largely in the oxidase 
form. XOR is associated with this membrane and may be released more 
readily from disrupted than from intact membrane, i.e. from thawed human 
milk than from intact membranes of fresh bovine milk. As a consequence, 
enzyme was probably largely lost in the initial stirring step in the case of 
human milk. In confirmation of this idea, the preparation of Sanders et al. 
has always given much higher yields when fresh human milk was used.
The nature of the association of XOR with the milk fat globule membrane 
is unclear. Milk fat globules are, however, known to be surrounded by 
glycosylaminoglycans (Welsch et al., 1988; Buchheim et al., 1988) to 
which XOR binds (Adachi etal., 1993; Radi et al., 1997). Elsewhere in this 
thesis, it is shown that HMXO binds more tightly to heparin than does 
HMXDH (Chapter 8) and it is tempting to explain the facilitated release of 
XOR from the milk fat globule effected by DTT in terms of conversion of 
XO to XDH and consequently decreased affinity to glycosaminoglycans.
A further point worthy of note is the increase in overall XOR activity 
observed following release from the cream. Two factors may contribute to 
this. Firstly, membrane association of XOR has been shown (Briley & 
Eisenthal, 1974; Briley & Eisenthal, 1975) to decrease activity to xanthine 
(and presumably pterin). Secondly, DTT in the releasing buffer converts
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the predominantly oxidase form of HMXOR to the dehydrogenase form, 
which, as shown in Section 8.2, shows intrinsically higher specific activity.
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5 Molecular Weight Estimation
5.1 Introduction
It has been previously reported that HMXOR has lower mobility than 
BMXOR on SDS-PAGE (Abadeh et al., 1992). In this chapter I describe 
the estimation of the molecular weights for HMXOR and BMXOR using a 
variety of well-established methods. These methods, with the exception of 
SDS-PAGE, estimate the molecular weight using the Stake's radius, and 
assume a roughly spherical conformation.
5.2 Materials and methods
5.2.1 SDS-PAGE
SDS-PAGE was carried out according to the method of Laemmli (1970). 
10% and 7.5% Resolving gels consisted of Protogel [stock solution of 
25% (w/v) acrylamide:bisacrylamide (40:1)] 40% (v/v) or 30% (v/v) 
respectively, in 0.375 M Tris-HCI, pH 8.8, containing 0.1% (w/v) SDS, 
polymerised by the addition of TEMED (0.4 pl/ml) and 0.1% (w/v) 
ammonium persulphate. 5% stacking gel consisted of Protogel [stock 
solution of 25% (w/v) acrylamide:bisacrylamide (40:1)] 20% (w/v) in 0.125
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Tris-HCI, pH 6.8, containing 0.1% (w/v) SDS, polymerised by the addition 
of TEMED (0.4pl/ml) and 0.1% (w/v) ammonium persulphate. Reservoir 
buffer was 25 mM Tris-HCI, pH 8.3, containing 0.192 M glycine and 0.1% 
(w/v) SDS. Samples, in low ionic strength buffer, were mixed 1:1 with 
sample buffer [62.5 mM Tris-HCI, pH 6.8, containing 0.1% (w/v) SDS, 50% 
(v/v) glycerol, 0.02% (w/v) bromophenol blue and mercaptoethanol (10 
pl/ml)] and denatured in a boiling water bath for 1.5 min before loading 
onto the gel. Gels were run at a constant voltage of 200 volts until the dye 
front reached the bottom of the gel. The stacking gel was removed and 
the resolving gel stained with staining buffer [distilled water containing 
35% (v/v) methanol, 10% (v/v) acetic acid and 0.1% (w/v) coomassie 
Brilliant Blue dye] for 1 h, then de-stained using de-staining buffer 
[distilled water containing 5% (v/v) methanol and 10% (v/v) acetic acid].
Molecular weights were estimated by construction of a standard curve of 
molecular weight against the log Rf (relative mobility, calculated from the 
migration distance of the protein divided by that of the dye front) of the 
high molecular weight standard mixture (Sigma).
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5.2.2 Native-PAGE
5%, 6%, 7% and 8% Gels and buffers were prepared as described in 
Section 5.2.2 with the omission of SDS and the concentration of 
acrylamide:bisacylamide was varied accordingly. Samples, in 25 mM 
sodium phosphate, pH 7.4, were mixed 1:1 with sample buffer and loaded 
onto the gels. Gels were electrophoresed at 5 milliamps until the marker 
dye was seen to have passed through the stacking gel and then at 10 
milliamps until the marker dye had reached the bottom of the gel. Gels 
were stained for protein as described in Section 5.2.2.
Non-denaturing protein molecular weight marker kit (sigma), was run on 
the same gel as the sample for molecular weight determinations. The Rf 
was calculated (Section 5.2) and the KR calculated from the slope 
produced by plotting 100 x Log (Rf x 100) against the % gel concentration 
for each protein. The molecular weights were estimated by constructing a 
standard curve of log -K R plotted against Log molecular weight.
5.2.3 Gel filtration
Sample (1 ml) was loaded onto a Hi Load 16/60 Prep Grade Superdex 
200 gel filtration column, capable of separating molecular weights of 10 - 
600 kDa, and chromatographed at a rate of 1 ml/min. Standards, dextran 
blue, yeast alcohol dehydrogenase, bovine serum albumin, carbonic
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anhydrase and dinitrophenyl lysine, were used to calibrate the column for 
molecular weight determination. Molecular weights were estimated by 





HMXOR and BMXOR, the latter both prepared by myself and purchased 
from Biozyme laboratories were run on SDS-PAGE (Section 5.2.1). Fig.
5.1 shows a stained 7.5% gel from which it can be clearly seen that 
HMXOR runs with a lower mobility than does BMXOR. Log Rf values were 
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Fig. 5.1. SDS-PAGE of HMXOR and BMXOR. Different amounts of 
HMXOR and BMXOR were run on a 7.5% SDS-PAGE gel and stained for 
protein as described in Section 5.2.1. Lanes 1, 3, 5 and 7, BMXOR 15 pg, 
5 pig, 10 pg, 15 pg, lanes 4, 6, and 8, HMXOR 5 pg, 10 pg, 15 pg, lanes 2 
and 9, High molecular weight markers.
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Fig. 5.2. Determination of the molecular weight of HMXOR and 
BMXOR by SDS-PAGE. As described in Section 5.2.1. Symbols 
represent; molecular weight standards (open squares), BMXOR (open 
circle) and HMXOR (filled circle).
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5.3.2 Native-PAGE
HMXOR and BMXOR were run on native-PAGE according to the method 
described in Section 5.2.2. Fig. 5.3 shows the native gels with 
concentrations of 5%, 6%, 7% & 8%. Rf and KR values were calculated 
and plotted as described in Section 5.2.2 (Fig. 5.4), and the molecular 
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Fig. 5.4. Determination of the molecular weights of HMXOR and 
BMXOR by Native-PAGE. As described in Section 5.2.2. Symbols 
represent; non-denaturing high molecular weight standards (open 
squares), BMXOR (open circle) and HMXOR (filled circle).
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Fig. 5.3. Native-PAGE of HMXOR and BMXOR HMXOR and BMXOR 
preparations were run on 5%, 6%, 7% and 8% Native-PAGE gels (Section 
5.2.1) and stained for protein (Section 5.2.1). Gels a, b, c and d, 
correspond to 5%, 6%, 7% and 8% gels respectively. Lanes 1 BSA; lanes 
2, BMXOR; lanes 3, HMXOR and lanes 4, Alcohol dehydrogenase (yeast).
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5.3.3 Gel filtration
Gel filtration was used to estimate the molecular weight of HMXOR and 
BMXOR as described in Section 5.2.3. Elution volume was plotted against 
log Mr (Fig. 5.5) and the molecular weights were estimated, (Table 5.1).
120 -
o  1 0 0
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Fig. 5.5. Determination of the molecular weight of HMXOR and 
BMXOR by FPLC on Superdex 200. As described in Section 5.2.3. 
Symbols represent; ADH (141 kDa), BSA (66.2 kDa), CA (31 kDa) and 
DNP-lysine (367 Da) (open squares), BMXOR (open circle) and HMXOR 
(filled circle).
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5.3.4 Dynamic Light Scattering
Dynamic light scattering was used to provide an estimation of Stoke’s 
radius and hence molecular weight (see Section 5.1). HMXOR and 
BMXOR samples, purified from fresh human and bovine milk, were used. 
The data indicated that the polydispersity figures were sufficiently low to 
suggest that samples were virtually monodisperse. Unlike other samples 
of HMXOR used in light scattering studies the enzyme used here, purified 
from fresh human milk in the presence of 10 mM DTT, was found to be 
virtually monodisperse. The results are shown in table 5.1.
HMXOR BMXOR
SDS PAGE 151 kDa (±2 kDa) 147 kDa (±2 kDa)
Native PAGE 277 kDa (±6 kDa) 267 kDa (±6 kDa)
Gel Filtration 311 kDa (±16 kDa) 273 kDa (±16 kDa)
Light Scattering 259 kDa (±8 kDa) 243 kDa (±1 kDa)
Table 5.1 Molecular weights determined by SDS-PAGE, native-PAGE, 
gel filtration and dynamic light scattering. As determined in Sections 
5.3.1, 5.3.2, 5.3.3 and 5.3.4.
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5.3 Discussion
The methods of estimating molecular weights, described here, 
consistently show slightly higher vales for HMXOR than for BMXOR. 
These findings contrast with those recently derived from MALDI-TOF 
mass spectrometry (R. C. Bray, personal communication) whereby values 
of 148 ± 0.7 kDa (n=12) and 148.3 ± 0.5 kDa (n=6) were obtained for 
HMXOR and BMXOR respectively. The amino acid sequence of BMXOR 
has been reported (Berglund et a/., 1996, see Appendix Section 12.1) and 
is consistent with a molecular weight, including a full complement of 
cofactors, of 148.3 kDa; clearly in excellent aggreement with MALDI-TOF 
MS. The primary sequence of human liver XOR (HLXOR) has also been 
reported (Ichida et a/., 1993, see Appendix Sections 12.1) and, although 
having 143 amino acid changes, is of essentially the same size. HMXOR 
has been sequenced (Briggs & Pearson, personal communication, see 
Appendix Section 12.3) apart from approximately 200 N-terminal residues 
and it is, so far, essentially identical to HLXOR.
It appears, therefore, that HMXOR and BMXOR could differ slightly in 
tertiary structure. HMXOR contains approximately 95% demolybdo form, 
compared with approximately 40% for BMXOR (Chapter 9) and, while the 
extent to which molybdenum cofactor contents parallel these percentages 
is not clear, it is possible that the higher content of demolybdo form in
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HMXOR will be reflected in a more open conformation, with increased 
Stake's radius. While this argument might serve to explain the results of 
native-PAGE, gel filtration and light scattering, it will not so serve for SDS- 
PAGE. Moreover, explanations based soley on an open conformation of 
demolybdo enzyme might predict more than one apparent value for 
BMXOR (40% demolybdo), which was never observed.
As noted above, differences in apparent molecular weight shown by SDS- 
PAGE, consistently observed in our laboratory over several years, cannot 
be explained in terms of tertiary structure. The possibility that HMXOR 
might be resistant to complete reduction and denaturation was considered 
and rejected following extended heating times in denaturing sample buffer 
(data not shown). It is known that a proline rich sequence can lead to low 
mobility on SDS-PAGE. Full comparison of amino acid sequences of 
HMXOR and BMXOR awaits data for the first 200 amino acids, apart from 
which the two enzymes are essentially identical. However, residues 193 - 
225 of BMXOR in the loop region between the Fe-S and FAD domains 
(Sato et al., 1995) contain 9 prolines in 32 residues and it will be 




Aggregation of HMXOR has been noted as a problem since its first 
characterisation (Abadeh et al., 1992). Visible aggregation has been 
observed after storage, during concentration or in thawing frozen 
solutions. Centrifugation to remove aggregated precipitates leads to loss 
of enzyme, the remaining solution having a relatively increased amount of 
soluble impurities. Aggregation is particularly a problem with HMXOR as it 
appears to aggregate more readily than BMXOR. This chapter describes 
attempts to characterise the nature of the aggregation observed with 
HMXOR.
Considerable effort was expended in attempts to use light scattering as a 
tool in these studies. Light scattering has been used to monitor the 
aggregation of proteins and other molecules (Yamamoto et al,. 1995; 
Asnaghi et al., 1995). Light scattering has the advantages that it is non­
destructive and requires small samples. Dynamic light scattering is based 
on the measurements of fluctuations in scattered light intensity caused by 
the relative movements of macromolecules in solution. The time scale of 
these fluctuations depends on the speed of movement of molecules 
moving under Brownian motion, allowing the translational diffusion
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coefficient (DT) to be obtained. Once DT has been determined, the 
hydrodynamic radius (RH) can be calculated by using the Stokes-Einstein 
equation. Molecular weights are then estimated using the relationship 
between molecular weight and RH determined for a series of standard 
proteins. In tables derived from dynamic light scattering studies four 
values are quoted. First the molecular weight (kDa) as estimated from the 
second value, the radius (nm). The third value is polydispersity (nm), 
which is the standard deviation for the radius and the fourth value is the 
baseline value. This is a statistical parameter which, at best is 1, indicates 
the reliability of the data measured.
Where aggregates of many different sizes are present in the solution, the 
dynamic light scattering generated values of molecular weight give an 
average. The values obtained can be interpreted to give an estimation of 
aggregation, as polydispersity is seen to increase with the molecular 
weight.
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6.2 Materials and methods
6.2.1 Native-PAGE
Native gels were prepared as described in Section 5.2.2 and stained for 
protein as described in Section 5.2.1 or activity by incubating at room 
temperature in 50 mM Tris HCI, pH 7.5, containing 20 mM xanthine and 3 
mM nitroblue tetrazolium chloride (NBT), until bands appeared, usually 
10-30 min (Waud & Rajagopalan, 1976 a).
6.2.2 Dynamic light scattering
XOR solutions (0.5 ml) in 50 mM Na-phosphate, pH 7.4, were injected into 
an Oros Instruments M801 Molecular Size Detector through a Whatman 
anotop 10 0.1 pm syringe filter using a 1 ml syringe. Data were handled 




Aggregated HMXOR samples were loaded onto the gel filtration column 
and eluted at a flow rate of 1 ml/min, as described in Section 5.2.3. Fig.
6.1 shows the elution profile of HMXOR. The largest peak, peak 1 was 
calculated to have a molecular weight of 311 ± 1 6  kDa, corresponding to 
HMXOR. Peak 2 was estimated to have a molecular weight of 
approximately 700 ± 122 kDa, although determinations of molecular 
weights as high as this are inaccurate, and peak 3 was eluted in the void 
volume. SDS-PAGE on fractions from all three peaks confirmed the 
presence of a 150 kDa protein band; however xanthine oxidase activity 
could only be detected in peaks 1 and 2, possibly because the 
concentration of XOR protein in peak three was too low.
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Fig . 6 .1 . F P L C  e lu tio n  p ro file  o f  a g g re g a te d  H M X O R  fro m  S u p e rd e x  
200. An aggregated sample of HMXOR was eluted at 1 ml/min on a 
Superdex 200 column as described in Section 6.3.1. Peak 1 corresponds 
to native HMXOR dimer («300 kDa), peak 2 corresponds to a tetramer 
(«700 kDa) and peak 3 is eluted in the void volume.
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6.3.2 Native-Page
Samples of HMXOR were run on native-PAGE. The gels were separately 
stained for protein and enzymic activity (Sections 5.2.1 & 6.2.1). Both gels 
(Fig. 6.2) showed similar staining, with the majority of protein and activity 
running as a band on the gels corresponding to HMXOR (Section 6.3.2). 
Despite considerable smearing a fainter band with lower mobility was 
observed on both protein- and activity-stained gels.
Fig. 6.2. Native-polyacrylamide gels (7.5%) of aggregated HMXOR.
Aggregated HMXOR was subjected to native-PAGE and the gel stained 
for activity (left) and protein (right) (Sections 6.2.1 & 5.2.1). Band 1 
corresponds to HMXOR with a molecular weight of 300 kDa. Band 2 
corresponds to a much larger species (weight not determined).
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6.3.3 Effect of concentration on aggregation of HMXOR
Freshly-prepared HMXOR and BMXOR solutions were diluted to 
concentrations of 1, 0.5 and 0.2 mg/ml, the last concentration being the 
lower iimit of detection for the dynamic light scattering detector. 10 min 
after dilution, samples were injected into the detector for estimation of 
molecular weight. The results, (Table 6.1), indicate that HMXOR was 
largely aggregated at all three concentrations. However, the aggregation, 
as judged by both the estimated molecular weight and the polydispersity, 
decreased with dilution. In contrast, the similarly-prepared BMXOR 












1.0 47693 54.8 30.4 1.03
0.5 39994 50.9 28.3 1.04
0.2 33564 47.4 26.3 1.04
BMXOR
2.0 292 6.7 1.7 1.00
0.5 282 6.6 1.8 1.01
Table 6.1. The effect of concentration on aggregation of HMXOR and 
BMXOR. HMXOR (1 mg/ml) was diluted to 0.5 mg/ml and 0.2 mg/ml and 
similarly prepared BMXOR, 2 mg/ml, was diluted to 0.5 mg/ml. The 
samples, 10 min after dilution, were subjected to dynamic light scattering 
for estimation of molecular weight as described in Section 6.2.2.
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6.3.4 Effect of NaCI on aggregation of HMXOR
1M NaCI solution was added to HMXOR and BMXOR so as to achieve the 
final concentrations shown in Table 6.2. 10 min after addition, samples 
were injected into the detector for estimation of molecular weight. The 
results, (6.2), show a trend of decreasing aggregation with increasing 
NaCI concentration. Again, BMXOR shows little or no aggregation even in 











0.0 47693 54.8 30.4 1.03
0.1 31356 46.1 25.5 1.04
0.2 27529 43.7 24.2 1.04
0.5 14983 34.0 18.8 1.04
BMXOR
0.0 292 6.7 1.7 1.00
0.1 273 6.5 1.6 1.00
Table 6.2. The effect of NaCI on aggregation of HMXOR and BMXOR.
To HMXOR (1 mg/ml) and to similarly-prepared BMXOR (2 mg/ml), NaCI 
was added to final concentrations of 0.1 M, 0.2 M and 0.5 M. The 
samples, 10 min after addition, were subjected to dynamic light scattering 
for estimation of molecular weight as described in Section 6.2.2.
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6.3.5 Effect of dithiothreitol on aggregation of HMXOR
DTT was added to a sample of HMXOR and injected into the detector for 
estimation of molecular weight. As a control, a sample which had no DTT 
added was also injected. The molecular weight was monitored over time 
and the results are shown in Fig. 6.3. HMXOR, without DTT added, did 
not change significantly over the time-course. In the presence of DTT the 
apparent molecular weight was seen to decrease significantly and to 
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Fig. 6.3. The effect of DTT on aggregation of HMXOR. 10 mM DTT was
added to aggregated HMXOR and the sample was injected into a dynamic 
light scattering molecular weight detector. The molecular weight was 
estimated over time (O). The same sample without DTT was also 
monitored ( • )  which showed a slight increase in molecular weight over 
the time-course.
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6.3.6 Activity of aggregated enzyme
A preparation of HMXOR displaying visible turbidity was centrifuged 
(13000g, 10 min.) and the pellet was redissolved in buffer containing 10 
mM DTT. Table 6.3 shows that the original sample, the centrifugate and 







HMXOR sample (62% Oxidase) 500 0.24 62.0 ± 6.0
supernatant after centrifugation 500 0.19 58.0 ±6.3
pellet after resuspending in DTT 130 0.06 70.0 ±4.2
Table 6.3. Xanthine oxidase activity of aggregated and soluble 
HMXOR. A sample of HMXOR in 50 mM Na Bicine, pH 8.3, that was 
visibly turbid was centrifuged (13000g 10 min). The resulting supernatant 
was decanted and the pellet was dissolved in 50mM Na Bicine, pH 8.3, 
containing 10mM DTT. For each of the three fractions xanthine oxidase 
activities (Section 3.2.3) and protein concentrations (Section 3.2.1) were 
measured and the specific activity calculated.
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6.4 Discussion
Gel filtration and native PAGE clearly show the presence of aggregates in 
samples of HMXOR, and the aggregated enzyme is showed to be 
enzymically active. HMXOR used in these experiments contained largely 
the demolybdo form (Chapter 10), which in the case of BMXOR has been 
more susceptible to denaturation under certain conditions (Bergel & Bray, 
1956; Ventom, et al., 1988). HMXOR in the present study was clearly 
more prone to aggregation than BMXOR, however, the aggregates 
appeared to be enzymically active and not denatured, as evidenced by 
gel filtration and native-PAGE. Moreover, aggregated HMXOR, removed 
by centrifugation, had a similar specific activity to that of soluble HMXOR.
The greater susceptibility to aggregation of active HMXOR, compared to 
BMXOR, presumably reflects some structural or charge differences 
between enzyme from the two sources. The essentially predictable effects 
of concentration and NaCI on aggregation of HMXOR provide few clues. 
The disaggregating effect of DTT, unlike that of NaCI, was time- 
dependant on a time scale with that of oxidase to dehdrogenase 
conversion (Chapter 8) suggesting that differences in aggregatability 





Because of the chromophores present in XOR, UV visible spectra can 
reveal much about the composition of the enzyme and also about 
functional differences between its different forms (Hille & Nishino, 1995). 
On a more practical level, a spectrum of a given sample of enzyme can 
allow an accurate determination of concentration and purity (Avis et al., 
1955). In preliminary studies, significant differences were observed 
between the spectra of HMXOR and BMXOR and these were investigated 
in the presently described work. In so far as all three chromophores of 
XOR, iron-sulphur, FAD and the molybdenum centre, are optically active, 
circular dichroism (CD) lends itself to study of the enzyme, although only 
a few relevant publications have appeared (Garbett et al., 1967; Palmer & 
Massey, 1969; Bayer et al., 1971; Hunt & Massey, 1992). In the present 
comparison of HMXOR and BMXOR, CD has proved to be particularly 
informative.
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7.2 Materials and Methods
7.2.1 Flavin estimations
To determine the e 45o of HMXOR and BMXOR preparations, the flavin 
fluorescence of the enzyme in 5% trichloracetic acid was compared to that 
of standard solutions of flavin. Enzyme samples in 50 mM phosphate 
buffer, pH 7.4, containing 5% TCA were incubated at 4°C for 30 min and 
centrifuged at 13000g for 10 min at 4°C. The flavin fluorescence at 525 
nm was measured with excitation at 450 nm in a Perkin-Elmer LS-5B 
Luminescence Spectrometer, and FAD was quantified ( e 45o = 11300M*1 
cm*1) by comparison with standard solutions of FAD.
7.2.2 UV-visible spectra
UV-visible spectra of enzyme samples in 50 mM phosphate buffer, pH 7.4, 
were recorded using a Cecil CE 6600 Multimode Computing UV 
Spectrophotometer. Data were collected by an IBM compatible personal 
computer using software designed and written by Dr R. Maytum.
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7.2.3 CD spectra
CD spectra of enzyme samples in 25 mM potassium phosphate, pH 7, 
were recorded by Dr. G Siligardi at the EPSRC National Chiroptical 
Spectroscopy & ULIRS Optical Spectroscopy Centres, King’s College 
London. Far-UV and UV-visible CD spectra were recorded using a Jasco 
J-600 and Jasco J-700 CD spectrophotometers respectively.
86
7.3 Results
7.3.1 Molar Extinction Coefficients
The flavin content of a sample of HMXOR and BMXOR and three samples 
of demolybdo BMXOR were determined (Section 7.2.1) and, on the 
assumption that each subunit contains its full complement of FAD, e450 
values were calculated from the UV-visible spectra. These values, shown 
in Table 7.1, can be compared with that of 36000M'1 cm'1 quoted by Bray 
(1975) for BMXOR containing its full complement of cofactors. Although, 
in my hands, BMXOR showed a value similar to that of Bray, the molar 
extinction coefficient for HMXOR was considerably lower at 28500 M '1 cm' 
1. Demolybdo BMXOR prepared by folate affinity chromatography (Section 
4.3.5) showed values intermediate between those of HMXOR and 
BMXOR.
Sample and Preparation Number A450 M FAD'1
HMXOR1 28500 ±1300
BMXOR 2 34800 ±1200
BMXOR 4 demolybdo 35000 ±1600
BMXOR 5 demolybdo 33300± 700
BMXOR 6 demolybdo 28600 ±1100
Table 7.1. Calculations of molar extinction coefficients from FAD 
estimations. FAD was estimated as described (Section 7.2.1) and used 




UV-visible spectra of HMXOR, BMXOR and demolybdo BMXOR 6 were 
measured and replotted at identical molarities, according to the FAD 
content (Fig. 7.1). The difference spectrum of HMXOR subtracted from 
BMXOR gave a spectrum similar to those of the non-haem Fe-S 
containing proteins (Shethna et al., 1968) (Fig. 7.1, inset), suggesting that 
HMXOR lacks Fe-S.
This apparent Fe-S deficiency was estimated from the extinction 
coefficients by using the following equation, based on the assumptions 
that enzyme with an e 4so 36000 M'1 cm'1 has 100% Fe-S content and that 
the absorbance at 450 nm is solely due to FAD and Fe-S.
% Deficiency = [1-(eM Sample - eM FAD) / (eM BMXOR - eM FAD )] x100
Where s „  B M X O R  = 3 6 0 0 0  M '1 cm'1, and eM FA D  = 1 1 3 0 0  M '1 cm'1
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Fig. 7.1. Near UV-visible absorption spectra of BMXOR, HMXOR and
demolybdo BMXOR. Spectra of BMXOR (--------- ); HMXOR ( );
demolybdo-BMXOR ( ) were taken at concentrations of 8.9, 8.1 and
3.1 pM respectively and replotted using the g 450 values in Table 7.1 to 
normalise them on the basis of FAD content. The lower curve is the 
difference spectrum after subtraction of the HMXOR spectra from the 
BMXOR spectra. Inset; Fe-S protein I (Shethna etal., 1968).
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BMXOR 2 1.90 4.9 2.00 0.0
HMXOR1 1.39 30.4 1.38 31.3
Demolybdo BMXOR 6 1.40 30.0 1.42 28.8
Table 7.2. Estimation of Fe-S/FAD ratios, and % Fe-S deficiencies 
from the UV-visible and CD spectra. Molar extinction coefficients (Table 
7.1) were used to calculate the Fe-S content and deficiencies from the 
UV-visible spectrums as described in Section 7.2.2. CD 342 nm molar 
extinction coefficients were used to calculate the Fe-S content and 
deficiencies as described in Section 7.3.4. * These data assume an 
Fe-S/FAD of 2 for BMXOR.
7.3.3 Simulation of the UV-visible spectrum of HMXOR
If we accept that HMXOR is 30% deficient in Fe-S (Table 7.2) then it 
should be possible to simulate the HMXOR spectra by addition of FAD 
spectra to the BMXOR spectra in such proportions as to recreate the ratio 
Fe-S/FAD of HMXOR. Fig. 7.2 shows the spectra of HMXOR, BMXOR + 
FAD and the difference spectrum. It can be seen that the simulated 
HMXOR spectrum agrees very well with that of HMXOR itself. Fig. 7.3 
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Fig. 7.2. Near UV-visible absorption spectra of HMXOR and simulated 
HMXOR. The spectra of HMXOR was simulated by computed addition of 
the spectra of BMXOR and FAD to give the same Fe-S/FAD ratio as
HMXOR (Table 7.2), as described in Section 7.3.3, (--------- ), and plotted
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Fig. 7.3. Near UV-visible absorption spectra of HMXOR and BMXOR.
The molar absorption spectra of BMXOR and HMXOR were replotted after 
that of HMXOR ( ) had been appropriately matched at 450nm to that
of BMXOR (--------- ).
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7.3.4 CD Spectra
Near-UV-visible CD spectra of HMXOR, BMXOR and demolybdo BMXOR 
6, were measured, and replotted at identical molarities according to their 
G450 values (Table 7.1). As can be seen in Fig. 7.4, above 350 nm, 
whereas all three spectra show essentially the same form, their intensities 
differ, with BMXOR showing markedly greater Cotton effects than HMXOR 
or demolybdo BMXOR 6. Spectra of the latter two species are remarkably 
similar. These CD spectra derive very largely from the Fe-S centres 
(Bayer et al., 1971) and provide further evidence of a deficiency of Fe-S 
centres for HMXOR and demolybdo BMXOR relative to BMXOR. CD G432 
values for HMXOR, BMXOR and demolybdo BMXOR 6 of 49.5, 34.0 and 
35.2 respectively were determined from the spectra and used to calculate 
Fe-S deficiencies assuming that BMXOR has a full complement of Fe-S 
and that Fe-S centres were solely contributing to the CD spectra at this 
wavelength (Table 7.2). If the CD spectra are normalised, replotting the 
data using the apparent Fe-S deficiency (Table 7.2) then, above 350 nm, 
all three spectra are much more similar (Fig. 7.5). Relatively small 
differences are still, however apparent, particularly in the 200-400 nm 
region as can be seen from Fig. 7.5. Other small differences in the 450 to 
750 region are highlighted in Fig. 7.6 which is a difference CD spectrum 
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F ig . 7 .4 . N e a r U V -v is ib le  m o la r  C D  s p e c tra  o f  H M X O R  ( ),
B M X O R  (------------) a n d  d e m o ly b d o  B M X O R  6 (--------- ). CD spectra were
determined and replotted using the near UV-visible molar absorption 
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Fig. 7.5. Near UV-visible CD spectra of HMXOR ( ), BMXOR
(--------- ) and demolybdo BMXOR 6 ( ) after normalisation for Fe-
S content. The molar CD spectra (Fig. 7.4) were replotted to normalise 
the Fe-S content (Table 7.2 column 1) to eliminate gross differences 
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Fig. 7.6. Near UV-visible CD difference spectra of BMXOR and 
HMXOR after elimination of gross Fe-S deficiency. The difference CD 
spectum was obtained after subtraction of BMXOR from the HMXOR CD 
spectra in Fig. 7.5, to provide a non Fe-S HMXOR - BMXOR difference 
spectra. Inset shows the reported Molv - Movl difference CD spectrum 
(Ryan et al. 1995).
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The far UV CD spectra of these samples was also measured, as shown in 
Fig. 7.7. These spectra, normalised for molarity, based on the extinction 
coefficients, are almost identical, indicating that the secondary structure 
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Fig . 7 .7 . F a r  U V  m o la r  C D  s p e c tra  o f  B M X O R  (------------), H M X O R
(------------) an d  d e m o ly b d o  B M X O R  ( ). Far UV CD spectra were




UV-Visible spectra of HMXOR and BMXOR, normalised on the basis of 
independently-measured FAD content, were found to differ significantly 
(Fig. 7.1), notably in their molar extinction coefficients at 450nm (Table 
7.1). Not surprisingly, samples of demolybdo BMXOR, individually 
prepared by folate-affinity chromatography (Section 4.3.5) and differing in 
their molybdenum contents, differed also in their UV-visible spectra and 
extinction coefficient at 450nm (Table 7.1). Nevertheless, one such 
example, demolybdo BMXOR 6, showed a UV-visible spectrum very 
similar to that of HMXOR and a correspondingly similar extinction 
coefficient (Table 7.1).
Difference spectra (BMXOR - HMXOR) (Fig. 7.1) showed a spectrum 
similar to that shown by Fe-S alone suggesting that HMXOR is deficient in 
Fe-S, relative to BMXOR, by approximately 30% (Table 7.2). As FAD and 
Fe-S are the major contributors to the UV-visible spectrum, it was decided 
to simulate the Fe-S/FAD ratio of HMXOR by computed addition of FAD to 
the BMXOR spectrum. As can be seen in Fig. 7.2, this led to a remarkable 
fit with the HMXOR spectrum. Small residual differences in the 300 - 400 
nm region were noted and may be attributable to the molybdenum 
cofactor which has been shown to have absorbance in this region with a
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maximum at 350 nm (Johnson et al., 1979). Other small residual 
differences could be attributable to the molybdenum.
The CD spectrum between 360 - 600 nm of BMXOR is known to result 
largely from the Fe-S groups (Bayer et al., 1971) and this is clearly 
reflected in the spectrum of HMXOR (Fig. 7.4), which shows an extinction 
coefficient at 432 nm of 34.0M'1 cm*1, compared with 49.5M'1 cm*1 for 
BMXOR; values that would be consistent with a Fe-S deficiency of 
approximately 30% for HMXOR. The CD spectrum of the demolybdo 
sample, BMXOR 6, was very similar to that of HMXOR, having an 
extinction coefficient at 432 nm of 35.2 M*1 cm*1, consistent with a Fe-S 
deficiency of 29% (Table 7.2). These values of Fe-S deficiency for 
HMXOR and demolybdo BMXOR relative to BMXOR are remarkably 
consistent with those obtained from UV-visible spectra (Table 7.2). The 
CD spectrum of BMXOR (Fig. 7.4) is very similar to those published by 
Palmer & Massey (1969) and Gardlik et al. (1987), although the extinction 
coefficient (432 nm) quoted by Palmer & Massey is somewhat lower at 48 
M*1 cm*1, whereas that quoted by Gardlik et al. is higher at 52 M*1 cm'1. 
The CD extinction coefficient for BMXOR after, allowance is made for Fe- 
S deficiency (Table 7.2, column 1), is 51.9 M'1 cm*1 (Fig. 7.5) which fits 
very well with that of Gardlik et al..
When the CD spectra of HMXOR and BMXOR were normalised on the 
basis of Fe-S values (Table 7.2), fits were good (Fig. 7.5), although
significant differences remain, as evidenced by the difference spectrum 
shown in Fig. 7.6. It is tempting to attribute these differences to FAD, the 
content of which would be relatively lower in the spectrum of BMXOR after 
normalisation. However, above 300 nm, FAD shows only a weak Cotton 
effect at 375 nm, with extinction coefficient of -0.32 M'1 cm'1, and 
negligible effects at higher wavelengths (Bayer et al. 1971; Siligardi, 
personal communication). It may be that differences in molybdenum 
content contribute to minor variations in the CD spectra above 350 nm. In 
this region, the CD spectrum of HMXOR is very similar to that of 
demolybdo BMXOR 6 (Fig. 7.4). Ryan et al. (1995) reported differences in 
CD spectra following reduction Molv to Movl and the corresponding 
difference spectrum (Fig. 7.6, inset) shows similarity to that for HMXOR - 
BMXOR (Fig. 7.6) above 430 nm.
Marked difference in the CD spectra of HMXOR, BMXOR and demolybdo 
BMXOR 6 are seen in the 300 - 350 nm region (Fig. 7.5). Cotton effects in 
this region have been attributed to the molybdenum cofactor (Gardlik et 
al. 1987) and indeed, Form A, one of its derivatives, shows a positive 
Cotton effect with a broad peak from 300 to 350 nm (Taylor et al., 1989). 
Differences in molybdenum cofactor content may, accordingly, explain 
differences, in intensities of the Cotton effects at 325 nm, between the 
three different enzymes.
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8 Oxidase and Dehydrogenase Forms of XOR
8.1 Introduction
It is known that human liver and milk XOR display the same general XDH 
to XO conversion characteristics as bovine milk and rat liver enzyme as 
very highly dehydrogenase form HMXOR can be obtained by incubation 
with DTT, and almost exclusively XO via trypsinisation (Abadeh et al., 
1992; Sanders et al., 1997) (see General Introduction). The production of 
non-proteolysed human XO and the non-proteolytic interconversions have 
not been described. Here the reversible interconversions of HMXOR are 
described in detail, with comparisons to the bovine milk enzyme. The 
methods that are used here have been shown to be successful in 
interconversions with the bovine milk and rat liver enzymes.
8.2 Materials and Methods
8.2.1 XO to XDH Conversion using Dithiothreitol
Samples of HMXO and BMXO were incubated at 37°C in Na-Bicine, pH 
8.3, containing 10 mM Dithiothreitol (DTT). Samples were taken regularly 
and assayed for xanthine oxidase activity in the presence and absence of 
NAD (Sections 3.2.3, 3.2.4). Xanthine oxidase activities were calculated
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and converted to specific activities and the percent oxidase activity was 
calculated (Section 3.2.4).
8.2.2 XDH to XO Conversion using Molecular Oxygen
Samples of HMXDH and BMXDH, previously converted with DTT, were 
incubated at 37°C in air-equilibrated Na-Bicine, pH 8.3. Samples were 
taken regularly and assayed for xanthine oxidase activity in the presence 
and absence of NAD (Sections 3.2.3, 3.2.4). Xanthine oxidase activities 
were calculated and converted to specific activities and the percent 
oxidase activity was calculated (Section 3.2.4).
8.2.3 XDH to XO Conversion using DTDP
HMXDH and BMXDH was incubated at 25 °C for 1 hour in 50 mM Na- 
bicine, pH 8.3, containing 1 mM 4,4 dithiodipyridine (DTDP). Samples 
before and after incubation were assayed for xanthine oxidase activity in 
the presence and absence of NAD (Sections 3.2.3, 3.2.4) and the percent 
oxidase activity was calculated (Section 3.2.4).
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8.2.4 Determination of free sulphydryl groups
HMXOR samples were incubated at 25°C in 50 mM Na-bicine, pH 8.3, 
containing 1 mM DTDP. The increase in absorbance at 324 nm was 
measured and the 4-thiopyridone concentration was calculated by an D325 
19800 M*1 cm'1 (Grassetti & Murray, 1967).
8.2.5 XDH to XO Conversions Using Oxidised Glutathione
BMXDH and HMXDH were incubated for 2h at 25°C in Na-bicine, pH 8.3, 
containing 10 mM oxidised glutathione. Samples before and after 
incubation were assayed for xanthine oxidase activity in the presence and 
absence of NAD (Sections 3.2.3, 3.2.4) and the percent oxidase activity 
was calculated (Section 3.2.4).
8.2.6 Heparin Affinity of HMXDH and HMXO
Samples of HMXOR were applied to a heparin agarose column (3 ml) and 
run on FPLC at a flow rate of 1 ml/min. Fractions were collected and the 
absorbance at 450 nm measured or assayed for xanthine dehydrogenase 
activity in the presence and absence of NAD (Sections 3.2.3, 3.2.4).
103
8.3 Results
8.3.1 XO to XDH Conversion using Dithiothreitol
Incubation of XO in 10 mM DTT caused the conversion to XDH. The time- 
scale of the conversions are shown in Figs. 8.1 and 8.2. The overall rate 
of conversion to HMXO and BMXO was similar. However, whereas the 
total specific activity for BMXOR decreased slightly during the conversion, 
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Fig. 8.1 Conversion of HMXO to HMXDH by treatment with DTT.
HMXO was incubated with an excess of DTT at 37°C as described in 
Section 8.2.1. Enzyme was assayed over the incubation and the specific 
xanthine oxidase activity and percentage of oxidase activity calculated. 














Fig. 8.2 Conversion of BMXO to BMXDH by treatment with DTT.
BMXO was incubated with an excess of DTT at 37°C as described in 
Section 8.2.1. Enzyme was assayed over the incubation and the specific 
xanthine oxidase activity and percentage of oxidase activity calculated. 
(O) total xanthine oxidase activity, ( • )  percentage oxidase activity.
8.3.2 XDH to XO Conversion using Molecular Oxygen
XDH samples were incubated in air-equilibrated buffer at 37°C. The time- 
course data are shown in Figs. 8.3 and 8.4. The oxidase conversions of 
BMXOR and HMXOR were markedly different, the rate of conversion of 
HMXOR was approximately 10 times slower and over the time-course the 
% oxidase activity of HMXOR increased to less than 50%. The total
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Fig. 8.3 Conversion of HMXDH to HMXO by incubation in air- 
equilibrated buffer at 37°C. HMXO was incubated in air equilibrated 
buffer at 37°C as described in Section 8.2.2. Enzyme was assayed over 
the incubation and the specific xanthine oxidase activity and percentage 
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Fig. 8.4 Conversion of BMXDH to BMXO by incubation in air- 
equilibrated buffer at 37°C. BMXO was incubated in air equilibrated 
buffer at 37°C as described in Section 8.2.2. Enzyme was assayed over 
the incubation and the specific xanthine oxidase activity and percentage 
of oxidase activity calculated. (O) total xanthine oxidase activity, ( • )  
percentage oxidase activity.
8.3.3 XDH to XO Conversion using DTDP
During the incubation of HMXOR in the presence of 1 mM DTDP, the 
percent oxidase activity increased from 11 % (± 2%) to 64% (± 2%), which 
was not further increased by prolonged incubation or addition of more 
DTDP. Untreated HMXO (75% oxidase) was incubated with DTDP as
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described above. However, the percentage oxidase of this sample 
remained unchanged. In similar experiments with BMXOR the percentage 
oxidase activity increased to 98.0 ± 2.0%. All these conversions were 
shown to be almost completely reversible to the original dehydrogenase 
activity by incubation with DTT.
8.3.4 Calculation of free sulphydryl groups
The method for assaying the free sulphydryl groups on xanthine oxidase 
is based on the method of Saito (1987). 4,4’-DTDP reacts with a 
sulphydryl group to form 4-thiopyridinyl-cysteine and 4-thiopyridone (Fig. 
8.6, scheme 1). The 4-thiopyridinyl-cysteine can then react with an 
adjacent sulphydryl group to form a disulphide bond and 4-thiopyridone 
(Fig. 8.6, scheme 2). In this way all available sulphydryl groups react 
producing an equimolar amount of 4-thiopyridone, which can be 
measured as described in Section 8.2.4.
The number of free sulphydryl groups involved in the conversion was 
examined with samples of HMXDH (11% ± 2.0% oxidase) and HMXO 
(75% ± 2% oxidase). The number of free sulphydryl groups in oxidase and 
dehydrogenase samples and the difference between them was calculated 





Fig. 8.5. The reaction of DTDP with vicinal thiols. 1) DTDP reacting 
with one vicinal thiol to produce 4-thiopyridinyl thiol and 4-thiopyridone. 2) 
4-thiopyridinyl thiol reacting with another local vicinal thiol to produce 4- 
thiopyridone and a disulphide bond.
4-Thiopyridone 
(mol/mol HMXOR)
HMXDH (10% Oxidase) 13.6 ± 0.8 (n=2)
HMXO (75% Oxidase) 7.6 ± 1.0 (n=2)
Difference 6.0
Table 8.1 Reactivity of HMXO and HMXDH with DTDP. HMXO and 
HMXDH were reacted with excess DTDP and the formation of 4- 
thiopyridone was monitored as described in Section 8.2.4. 4-thiopyridone 






























8.3.5 XDH to XO Conversions Using Oxidised Glutathione
After incubation with oxidised glutathione, BMXOR was found to have 
96% oxidase activity, whereas HMXOR was found to have 45% oxidase 
activity. Addition of protein disulphide isomerase to HMXOR did not 
significantly effect the percentage oxidase activity.
8.3.6 Heparin Affinity of HMXDH and HMXO
HMXOR samples (1 mg): unproteolysed HMXO (71% oxidase) prepared 
by exclusion of DTT from the preparation procedure, unproteolysed 
HMXDH (8% oxidase) and trypsinised HMXO after incubation with DTT 
(88% oxidase) were run on FPLC using a heparin column as described in 
Section 8.2.6. The elution profiles are shown in Fig. 8.6. The peaks of 
eluted enzyme in molar NaCI were at 0.35, 0.275 and 0.267 for the 
unproteolysed HMXO, unproteolysed HMXDH and DTT treated 
proteolysed HMXO respectively.
This experiment indicated a means of separation of the oxidase from the 
dehydrogenase form of HMXOR. A sample of HMXOR (60 % oxidase) 
prepared in the presence of DTT, but stored and frozen in its absence, 
containing a mixture of XO and XDH was applied to the column. The 
sample eluted as a main peak and a considerable shoulder, at 0.25 and 
0.32 M NaCI, shown in Fig. 8.7. These corresponded to the
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dehydrogenase and unproteolysed oxidase forms respectively, however 
the percentages of oxidase forms in both the peak and the shoulder were 
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Fig. 8.6. Affinity of HMXOR forms for heparin. HMXOR samples were 
applied to a heparin agarose column and eluted in a linear gradient of 
NaCI as described in Section 8.2.6. Fractions were collected and the 
absorbance at 450 nm measured. Samples were HMXDH (□), 
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Fig. 8.7. Elution profile of HMXOR (60% oxidase) from heparin 
agarose. HMXOR was applied to a heparin agarose column and eluted in 
a linear gradient of NaCI as described in Section 8.2.6. Fractions were 
assayed for xanthine oxidase activity in the presence (O) and in the 
absence ( • )  of NAD.
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8.4 Discussion
The XO to XDH conversion of BMXOR with DTT proceeded similarly to 
those previously reported for the bovine milk and rat liver enzyme 
(Nakamura & Yamakazi, 1982; Saito, 1987). The XDH to XO conversions 
of BMXOR with molecular oxygen and DTDP were also similar to those 
previously reported (Nakamura & Yamakazi, 1982; Waud & Rajagopalan, 
1976 b; Saito, 1987; Hunt & Massey, 1992; Stirpe & Della-Corte, 1969). 
The XO to XDH conversion of HMXOR using DTT was found to be very 
similar to that of BMXOR. However, the XDH to XO conversions of 
HMXOR under identical conditions proceeded very slowly and did not 
reach the very high percentage oxidase activity of BMXOR. A similar 
finding was observed when HMXOR was converted to the oxidase form in 
the presence of oxidised glutathione. In contrast to this, proteolysis of 
HMXOR with trypsin (see Section 8.3.6) was found to yield very largely 
HMXO.
Saito (1987) reports that chemical modification of sulphydryl groups with 
reagents such as N-ethylmaleimide inhibits full thiol induced conversion to 
the oxidase enzyme. Therefore it was considered that in our HMXOR 
preparations some molecules may have modified sulphydryl groups, 
possibly as a result of the preparation procedure, which interferes with 
disulphide bond formation. However, this possibility was dismissed as 
HMXDH reacted with DTDP to yield 13.6 moles of thiopyridone per mole
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of subunit, which matched previous findings in which complete conversion 
occurred (Waud & Rajagopalan, 1976 b). HMXO (75 % oxidase form), 
was shown to yield 7.6 moles of thiopyridone per mole of subunit, 
indicating that 75% oxidase enzyme has on average 6 moles of oxidised 
sulphydryl groups relating to three disulphide bonds per subunit. 
Extrapolating this to 100% oxidase enzyme would give 8 oxidised 
disulphides relating to 4 disulphide bonds. This value fits very well with 
the reported value of bovine milk and rat liver XOR which requires the 
oxidation of 8 sulphydryl groups per subunit for conversion to the oxidase 
form (Hunt & Massey, 1992; Waud & Rajagopalan, 1976 b; Saito, 1987).
Waud and Rajagopalan (1976 b) demonstrated that for the conversion of 
rat liver XDH to XO, the addition of sulphydryl oxidising reagents was 
necessary. They also showed that the rapid oxidation of sulphydryl 
groups, of which some are not involved in the conversion, was followed by 
a slower change in oxidase activity and therefore postulated that, after 
oxidation, an additional conformational change was required to cause the 
conversion. Although HMXDH was seen to oxidise fully, using DTDP, the 
conversion to the oxidase form did not proceed to its full extent. Therefore 
the required change in conformation for HMXOR may be either too slow to 
determine or may be disfavoured.
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The heparin affinity of HMXO and HMXDH was investigated, revealing a 
difference in heparin affinity between HMXO and HMXDH, judged by the 
peak elution in a gradient of NaCI. The peptides which exhibit the heparin 
binding capacity in HMXOR (Fukushima et al., 1995) have been 
determined, and relate to two sequences within the molybdenum domain. 
Although these peptides have not yet been localised in the XOR 
molecule, I extrapolated the peptides to those corresponding amino acids 
in aldehyde oxidoreductase (see Appendix, Section 12.2), a molybdenum 
containing iron-sulphur enzyme with high sequence homology to XOR and 
a member of the XOR protein family (Thoenes et al., 1994) where the 
structure is known (Romao et al., 1995). These peptides were seen to be 
localised on the surface of XOR (Fig. 8.8).
Both heparin binding peptides are basic, providing the positive charges 
required for binding to a sulphated glycosaminoglycan, and one of these 
peptides has been proposed to exist in a helical conformation where the 
basic residues are localised on one face of the helix (Fukushima et al., 
1995).
HMXO was found to have a higher affinity for heparin than HMXDH and 
trypsinised HMXO after incubation with DTT. The heparin binding 
capacity of HMXOR appears to be decreased by its reduction with DTT, 
which implies that, as in the XDH to XO conversion, disulphide bonds are 
involved. The
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F ig . 8 .8 . C ry s ta l s tru c tu re  o f  a ld e h y d e  o x id o re d u c ta s e  s h o w in g  th e  
p o s it io n s  o f  th e  h e p a rin  a ffin ity  p e p tid e s  (h ig h lig h te d  in b lu e ). The
protein sequences of HMXOR and AOR from Desulfovibrio gigas were 
aligned and the amino acids relating to the heparin affinity peptides of 
HMXOR, amino acids 781 to 795 and 1106 to 1122, were determined. 
These AOR amino acids, 403 to 417 and 720 to 733, were then 
highlighted in the crystal structure of AOR using Rasmol modelling 
software.
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formation of these bonds may be responsible for a change in orientation 
of the heparin binding peptides, therefore altering their heparin affinity. 
DTT reduced proteolysed HMXO (88% oxidase), which has been shown 
to have a similar number of free sulphydyl groups as XDH (Waud & 
Rajagopalan, 1976 b), has a similar elution profile to that of reduced 
HMXDH, indicating that different factors effect the heparin affinity than 
those which determine the oxidase activity. In addition, a preparation of 
HMXOR containing an intermediate amount of XO and XDH was not 
separated by heparin on the basis of oxidase activity. Intriguingly, 
although most of the activity was in the oxidase form, most of the protein 
elutes in the same position as the reduced enzyme. These experiments 
point to a sulphydryl oxidisable increase in heparin affinity for HMXOR, 
which is independent of that involved in the XDH to XO conversion and 
also indicates that the existence of oxidase form does not effect the 
oxidisable heparin affinity. The presence of the heparin affinity peptides at 
the surface of the molybdenum domain indicates a disulphide bond 
formation in this locality, which is different to the disulphide bond or bonds 
formed during the conversion of XDH to XO. The latter have been thought 
to be located in or close to the FAD domain. It has been shown that during 
oxidation of XDH there are 4 disulphide bonds formed, yet not all of these 
are involved in the D to 0  conversion (Saito, 1987). Therefore it seems 





It has been previously reported that purified HMXOR shows very low 
activity to most reducing substrates, compared to BMXOR (Abadeh et al., 
1992). Uniquely, activity toward NADH, which directly reduces FAD rather 
than molybdenum is similar to that of BMXOR (Sanders et al., 1997). The 
early data of Abadeh et al. were generated with enzyme considerably less 
pure than that recently available, and those of Sanders et al., while 
derived from enzyme of high purity were largely confined to NADH 
oxidase activities. In this chapter, I describe experiments designed to 
determine kinetic parameters for HMXDH and HMXO and, where possible, 
to compare them with those for BMXOR. In view of significant variation in 
the molybdenum site activity between batches of HMXOR, comparisons 
were in many cases done by using a single large batch of purified 
enzyme.
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9.2 Materials and Methods
9.2.1 Steady-state kinetic assays
Steady-state kinetic studies of xanthine oxidase activity were carried out 
in air-saturated 50 mM Na-Bicine, pH 8.3, at 25°C. XO and XDH assays 
were carried out in the absence and presence respectively of 500 pM 
NAD+. The rate of oxidation of xanthine to uric acid was measured 
spectrophotometrically at 295 nm, using an absorption coefficient for uric 
acid of 9600 M'1 cm'1 (Avis et al., 1956 a).
NADH oxidase assays were carried out at 25°C in air-saturated 50 mM 
MES at pH 6.5, 50 mM sodium phosphate at pH 7.4 and 50 mM MOPS at 
pH 7.5. The rate of oxidation of NADH to NAD+ was measured 
spectrophotometrically at 340 nm, by using an absorption coefficient for 
NADH of 6220 M'1 cm'1 (Horecker & Kornberg, 1948).
Superoxide production was determined in terms of superoxide-dismutase- 
inhibitable (30 units) reduction of 25 pM cytochrome c (horse heart), 
monitored at 550 nm and calculated by using an absorption coefficient for 
reduced cytochrome C of 21000 M'1 cm'1 (Massey, 1959).
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For substrates that cannot be monitored directly, assays were performed 
according to Krenitsky et al. (1986). Steady-state kinetic assays were 
performed at 37°C in 50 mM potassium phosphate, pH 6.8, containing 0.3 
mM EDTA, 0.3 mM phenazine ethosulphate (PES), and 0.08 mM 
cytochrome C (horse heart). The reduction of cytochrome C was 
monitored at 550 nm and calculated by using an absorption coefficient for 
reduced cytochrome C of 21000 M'1 cm'1 (Massey, 1959).
Data were analysed by using ENZPAC software which fits data to the 
Michaelis-Menten equation and calculates kinetic constants using the 
direct linear method of Eisenthal & Cornish-Bowden (1974). The program 
calculates values of Km and Vmax with errors expressed as 68% confidence 
limits.
9.2.2 pH Profiles
pH Profiles were determined by measuring the rate of oxidation at 25°C of 
100 pM xanthine or NADH in the presence of 500 pM NAD+ (Section 
3.2.3), in air-saturated 50 mM MES at pH 6 and pH 6.5, 50 mM MOPS at 
pH 7 and pH 7.5, 50 mM Bicine at pH 8, pH 8.3 and pH 8.5 and 50 mM 
CHES at pH 9.
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9.2.3 Quantification of intermediates in purine oxidation to urate
Cleere et al. (1975) describe a mathematical procedure for the estimation 
of hypoxanthine and xanthine intermediates in the oxidation of purine to 
urate. Isosbestic points were determined from spectra of purine, 
hypoxanthine, xanthine and urate at equimolar concentrations. Using 
these isosbestic points, the concentrations of the substrates can be 
calculated from UV absorption spectra of the reaction of purine with 
HMXOR using the following equations:
F xu1 (Ah2 "Axu2)"F xu2(Ahi"Axu1 )"^ (Axu2Ahl“Axu1 Ah2)
P= ------------------------------------------------------------
Api (Ah2-Axu2)“Ap2( Ahi -Axul )+(Axu2Ahl -Axu1 Ah2)
F xu1 (Ap2-Axu2)_F XU 2(AP1 “Axu1 )+(AXu2Api -Axul Ap2)
H = ------------------------------------------------------------
Ahi (AP2-Axu2)-Ah2(Api -Axui )+(Axu2Api -Axui AP2)
P = concentration of purine 
H = concentration of hypoxanthine
F = experimentally derived absorbance at the xanthine urate isosbestic 
points 1 and 2, Fxui and Fxu2 respectively 
A = absorbance of the intermediate from the standard spectra at the
xanthine urate isosbestic points 1 and 2, eg. Ahi is the absorbance 
of hypoxanthine and A xui is the absorbance of xanthine (or urate) 
at the xanthine urate isosbestic point 1.




9.3.1 Xanthine dehydrogenase and oxidase activities of HMXOR and 
BMXOR
Assays were performed over a range of xanthine concentrations from 
1 pM to 100 pM. Steady-state kinetic parameters for the oxidation of 
xanthine by human and bovine XO and XDH are shown in Table 9.1. The 
percentage oxidase activities of the samples were determined as 









Km(pM) 10.1 4.8 8.8 7.3
(9.1-12.7) (4.3-S.2) (8.1-9.5) (6.7-8.0)
vmax (nmol 82.5 1377 35.8 1359
min'1 mg'1) (78.5-96.5) (1353-1400) (34.6-36.2) (1330-1405)
Table 9.1. Kinetic parameters for xanthine oxidation by human and 
bovine XDH and XO. Assays were carried out in air-saturated 50 mM Na- 
Bicine, pH 8.3, as described in Section 9.2.1, For XDH assays, 500pM 
NAD+ was additionally present. Percentage values in brackets relate to 
oxidase contents of the enzyme determined as described in Section 3.2.4. 
68% Confidence limits for the calculated parameters are also shown in 
parentheses.
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9.3.2 NADH oxidase activities of human XDH and XO
Assays were performed over a range of NADH concentrations from 0.5 
pM to 100 pM. Steady-state kinetic parameters for the oxidation of NADH 
by human XO and XDH are shown in Table 9.2. The percentage oxidase 
activities of the samples were determined as described in Section 3.2.4.
HMXDH (9%) HMXO (68%)
Km(pM) 1.0 2.2
(0.8-1.1) (1.8-2.5)
Vmax (nmol min'1 mg'1) 124.3 88.8
(124.3-125.5) (86.2-90.7)
Table 9.2. Kinetic parameters for NADH oxidation by human XDH and
XO. Assays were performed in air-saturated 50 mM sodium phosphate, 
pH 7.4, as described in Section 9.2.1. Percentage values in brackets 
relate to oxidase contents of the enzyme determined as described in 
Section 3.2.4. 68% Confidence limits for the calculated parameters are 
also shown in parentheses.
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9.3.3 pH Profiles of total xanthine oxidase and NADH oxidase 
activities of HMXO and HMXDH
HMXO (60 % oxidase) was assayed for total xanthine oxidase activity in 
buffers of different pH containing 100 pM xanthine and 500 pM NAD+ as 
described in Section 3.2.3. HMXDH (9 % oxidase) was assayed for NADH 
oxidase activity in buffers of different pH containing 100pM NADH 
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Fig. 9.1. pH-Dependence of total xanthine oxidase and NADH oxidase 
activities of HMXO and HMXDH (60% and 9% oxidase respectively).
Xanthine oxidase ( • )  and NADH oxidase (O) activities of HMXO and 
HMXDH were assayed as described in Section 9.2.2 at pH values 
between 6 and 9.
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9.3.4 Comparison of substrate specificities of HMXOR and BMXOR
Assays were performed using the PES cytochrome C assay of Krenitsky 
et al. (1986), as described in Section 9.2.1. Steady-state kinetic 
parameters for the oxidation of purine, hypoxanthine, xanthine and 





































HLXO (Krenitsky et a/.) BMXO (Krenitsky et at.)
Km(pM) Vmax (%X) Km (pM) Vmax (%X)
Purine <1.0 >1.4 0.7 6.3
Hypoxanthine 9.0 220.0 6.0 175.0
Xanthine 7.0 100.0 8.0 100.0
2-APR 890.0 6.3 4000.0 61.0
Table 9.3. Kinetic parameters for the oxidation of purine, 
hypoxanthine, xanthine and 2-aminopurine ribonucleoside by HMXO 
and BMXO (9% and 68% oxidase respectively). Substrate-dependent 
PES cytochrome C assays were performed as described in Section 9.2.1. 
The values of Vmax are expressed as a percentage of that for xanthine. 
The values in brackets relate to 68% confidence limits for the calculated 
parameters. Also included for comparison are the data of Krenitsky et at. 
(1986) for human liver XO (HLXO) and BMXO. These workers quote 
average standard errors for their Km values of ±13% and for their Vmax 
values of ±5%.
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9.3.5 Quantification of intermediates in the oxidation of purine to 
urate catalysed by HMXO
UV absorbance spectra of 0.1 mM purine, hypoxanthine, xanthine and uric 
acid in 50 mM potassium phosphate buffer, pH 7.8, at 25°C, are shown in 
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Fig. 9.2. Ultraviolet absorbance spectra of equimolar concentrations 
of purine, hypoxanthine, xanthine and uric acid. The concentration of 
each compound was 0.1 mM in 50 mM potassium phosphate buffer, pH 
7.8, at 25°C.
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HMXO (0.175 mg) was added to 0.1 mM purine in 50 mM potassium 
phosphate buffer, pH 7.8, and the spectra of the mixture were taken 
periodically until the purine was nearly exhausted. Selected spectra are 
shown in Fig. 9.3, and the values at the predetermined isosbestic points 
were used to calculate the concentrations of the intermediates over time 
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Fig. 9.3. Ultraviolet absorbance spectra of purine oxidation by HMXO.
HMXO (68 % oxidase) (1.5 nmol), was added to 0.1 mM purine in 50 mM 
potassium phosphate, pH 7.8, and incubated at 25°C. Spectra were 












Fig. 9.4. Time course of purine oxidation by HMXO. Concentrations of 
intermediates in the time-course of purine oxidation by HMXO were 
calculated as described in Section 9.2.3. The graph shows the utilisation
of purine (------- ), the production of urate ( ------- ), and the formation of the
intermediates hypoxanthine (........) and xanthine (--------).
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9.3.6 pH Profile of NADH oxidase activity and superoxide production 
by HMXDH
NADH oxidase activity of HMXDH was monitored as a function of pH, in 
buffers with pH ranging from 6 to 8 containing 500 pM NADH, as 
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Fig. 9.5. pH-Dependence of NADH oxidase activity and superoxide 
production by HMXDH. NADH oxidase activity (■) of HMXDH was 
assayed as described in Section 9.2.2 at pH values between 6 and 8. 
Superoxide production ( • )  was also measured as described in Section 
9.2.1 and the percentage of electron flux to superoxide (O) was 
calculated. Error bars relate to standard errors with n=3.
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enzymic NADH degradation was observed, however at pH 6 a rate of non- 
enzymic degradation of 0.2 pM NADH min’1 was observed which was 
subtracted from the rates. Superoxide production from the oxidation of 
NADH over the range of pH was also monitored as described in Section 
9.2.1. From these data the percentage of electron flux to superoxide was 
calculated and is shown, together with the other data in Fig. 9.5.
9.3.7 NADH oxidase activity of HMXDH at pH 6.5 and pH 7.5
Assays on HMXDH were performed over a range of NADH concentrations 
from 0.5 pM to 50 pM at pH 6.5 and pH 7.5 to obtain the steady-state 
kinetic constants for the oxidation of NADH as described in Section 9.2.1. 
the calculated constants Km and Vmaxare shown in Table 9.4.
pH Km(pM) Vmax (nmol/min/mg)
6.5 0.59 146
(0.52 - 0.65) (143-147)
7.5 1.08 123
(0.99-1.20) (119-126)
Table 9.4. Kinetic parameters for NADH oxidation by HMXDH at pH
6.5 and pH 7.5. Assays were performed in air-saturated 50 mM MES, pH 
6.5, and 50 mM MOPS, pH 7.5, as described in Section 9.2.1. The values 
in brackets relate to 68% confidence limits for the calculated parameters.
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A separate set of experiments was carried out to determine the relative 
proportions of superoxide and hydrogen peroxide produced. The rates of 
NADH oxidation and superoxide production were monitored at pH 6.5 and 
pH 7.5 as described in Section 9.2.1 and are shown in Fig. 9.6 and Fig. 
9.7 respectively. From these data the percentage electron flux to 
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Fig. 9.6. NADH oxidation by HMXDH at pH 7.5 and pH 6.5. NADH 
oxidation was measured spectrophotometrically as described in Section 
9.2.1 in air-saturated 50 mM MOPS, pH 7.5, (O) and 50 mM MES, pH 6.5, 
(•) . The data were fitted to Michaelis-Menton curves using the figures in 
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Fig. 9.7. Superoxide production by HMXDH at pH 7.5 and pH 6.5. The
rates of superoxide were determined as described in Section 9.2.1 in air- 
saturated 50 mM MOPS, pH 7.5, (O) and 50 mM MES, pH 6.5, (•) . Error 









Fig. 9.8. The % electron flux to superoxide from the oxidation of 
NADH by HMXDH at pH 7.5 and pH 6.5. The percentage electron flux to 
superoxide was calculated from the data in Fig. 9.6 and Fig. 9.7 in air- 
saturated 50 mM MOPS, pH 7.5, (O) and 50 mM MES, pH 6.5, (•) . Error 
bars relate to standard errors with n=3.
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9.3.8 Effect of NAD* on superoxide generation catalysed by HMXDH 
in the presence of xanthine
Oxidation of xanthine (100pM) catalysed by HMXDH with and without 
500 pM NAD* in air-saturated 50 mM sodium phosphate, pH 7.4, and 
50 mM MES, pH 6.5, was monitored (Section 9.2.1). NADH production 
was also measured spectrophotometrically by monitoring the increase in 
absorbance at 340 nm, using an absorption coefficient for NADH of 6220 
M'1 cm'1 (Horecker & Kornberg, 1948). The results are shown in (Table 
9.5).






7.4 12.9 70.5 16.6
6.5 13.6 43.7 42.7
Table 9.5. The effect of NAD* on % oxidase and dehydrogenase 
activities of HMXO at pH 7.4 and pH 6.5. The percentage oxidase 
activity was measured as described in Section 3.2.4 in air-saturated 50 
mM sodium phosphate pH 7.4 and 50 mM MES pH 6.5 at 25°C. The 
percentage dehydrogenase activity in the presence of 500pM NAD* was 
calculated as described in section 9.3.8. The remaining xanthine oxidase 
activity after subtraction of the oxidase and dehydrogenase activities is 
also shown.
135
Calculation of the electron flux to oxygen by monitoring xanthine oxidation 
in the absence of NAD+ (Section 3.2.4), accounts for only 13% of that in 
the presence of 500 pM NAD+ at pH 7.4 and pH 6.5. This demonstrates 
that at least 87% of the electrons from xanthine should reduce NAD+ in 
the presence of 500 pM NAD+. However, the production of NADH was 
monitored and accounts for only 71% and 44% of the xanthine oxidised at 
pH 7.4 and 6.5 respectively, a difference of 29% and 56% at the 
respective pH. These conflicting results suggest that in the presence of 
NAD+, the flux of electrons to oxygen is actually increased from 13% to 
29% or to 56%, at pH 7.5 and 6.5 respectively.
HMXDH (8% oxidase) was assayed in air-saturated 50 mM MES, pH 6.5, 
containing 100 pM xanthine, and concentrations of NAD+ from 0 to 
500 pM. Xanthine oxidation was monitored at 295 nm and NAD+ reduction 
was monitored at 340 nm as described above and the rates of xanthine 
oxidation were calculated (Fig. 9.9). The data show that addition of 2 to 
500 pM NAD+ increases the rate of urate production by HMXDH. NADH 
production was not observed at any NAD+ concentration except at 500|uM 
NAD+. At lower NAD+ concentrations, as NADH production was not 
observed, the flux of electrons to oxygen must account for the total 
amount of xanthine utilised. At 500|iM NAD+ significant NADH production 
was seen which initially accounted for approximately 44% of the xanthine 
oxidised, as described above. The data from the time course of this assay
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over 20 min of turnover were plotted (Fig. 9.10) which show that the rate 
of NADH production was not sustained during the oxidation of xanthine, 
and after 10 min the NADH that was initially produced is oxidised.
30
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Fig. 9.9. The rate of urate production of HMXDH in the presence of 
varying concentrations of NAD+. HMXDH was assayed at 25°C in air- 
saturated 50 mM MES, pH 6.5, containing 100 pM xanthine and 0 to 
500pM NAD+. Urate production was monitored at 295 nm and was 
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Fig. 9.10. Urate and NADH production during turnover with HMXDH.
HMXDH was assayed at 25°C in air-saturated 50 mM MES, pH 6.5, 
containing 100 pM xanthine and 500pM NAD+. Urate production was 
monitored at 295 nm and NADH production was monitored at 340 nm and 
the amounts of xanthine oxidised and NADH produced were calculated as 
described in Section 9.2.1.
The fate of the electrons reducing oxygen was considered by monitoring 
the production of superoxide in the above system. HMXDH was assayed 
in air-saturated 50 mM MES, pH 6.5, containing 100 pM xanthine, 25 pM 
cytochrome C and concentrations of NAD+ from 0 to 500 pM. Cytochrome 
C reduction was monitored at 550 nm as described in Section 9.2.1 and 
the rates of superoxide production and percentage flux of electrons to 
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Fig. 9.11. The effect of NAD+ on superoxide production of HMXDH in 
the presence of xanthine. HMXDH was assayed at 25°C in air-saturated 
50 mM MES, pH 6.5, containing 50 pM xanthine, 25pM cytochrome C and 
0 to 200pM NAD+. Cytochrome C was monitored at 550 nm and the rate of 
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Figure 9.12. The % electron flux to superoxide from the oxidation of 
Xanthine in the presence of varying concentrations of NAD+. The
percentage electron flux to superoxide was calculated from the data in 
Fig. 9.9 and Fig 9.11 as described in Section 9.3.8.
The data show that addition of 2 to 500 pM NAD+ increases the rate of 
xanthine oxidation, yet only at the highest NAD+ concentration was NADH 
production detected. Superoxide production was greatest at 10 pM NAD+. 
The % flux of electrons to superoxide was highest at the lowest 
concentration of NAD+ (2 pM) where it accounted for 80 % of all xanthine 
oxidised.
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The largest rate of superoxide production by HMXDH from xanthine 
(100 pM) was in the presence of 10pM NAD+. This concentration was 
studied at the more physiologically relevant pH of 7.5. HMXDH was 
assayed in 50 mM MOPS, pH 7.5, containing 100 pM xanthine, 25 pM 
cytochrome C, with and without 10 pM NAD+. Urate production and 
cytochrome C reduction was monitored and the rates of xanthine oxidation 
and superoxide production were calculated (Section 9.2.1). From this the 
percent flux of electrons to superoxide was determined (Table 9.6). Here 
we see that the consumption of xanthine by HMXDH increases by 
approximately 50% in the presence of 10 mM NAD+, the production of 
superoxide increases by 180% and the percent flux of electrons to 







electron flux to 0 2 
(%)
0 18.3 ±0.0 7.1 ±0.7 19.6 ±4.7
10 26.6 ± 0.8 19.8 ±0.6 37.3 ±3.0
Table 9.6. The effect of NAD+ on the flux of electrons from xanthine 
to superoxide at pH 7.5. HMXDH was assayed for xanthine oxidation 
and superoxide production in 50 mM MOPS, pH 7.5 at 25°C in the 
absence and presence of 10 pM NAD+ as described in Section 9.2.1. The 




The Michaelis constants for the oxidation of xanthine by BMXO (Table 
9.1) are in agreement with those of Hille and Nishino (1995), the Km for 
xanthine oxidation by BMXDH was 10 fold higher than that determined 
previously (Hunt & Massey, 1992) but these workers used NADH 
production to assay activity, an assay that for reasons of comparison with 
HMXDH, was not chosen as it appears flawed for low molybdenum 
enzymes. The Vmax values for xanthine oxidation by HMXOR were very 
much lower than those of BMXOR under identical conditions (Table 9.1). 
HMXO and HMXDH showed similar Km values but the Vmax of the oxidase 
form is significantly lower.
The NADH oxidase activities of HMXDH and HMXO (Table 9.2) were 
found to have similar Michaelis constants to those published (Sanders et 
a/., 1997). The oxidase form has a lower Vmax than that of the 
dehydrogenase and the Km of the oxidase form is double that of the 
dehydrogenase. The specific activities of NADH oxidation for HMXDH and 
BMXDH were found to be identical after taking into account the 
differences in molar extinction coefficients (Table 7.1).
The pH profiles of xanthine and NADH oxidation by HMXO (Fig 9.1) are 
very similar to those published for BMXO (Briley & Eisenthal, 1974; Bray 
et al., 1996) showing pH maxima at 8.3 and 6.5 for xanthine and NADH
oxidation respectively. It is worth noting that human milk has a pH of 6.5, 
optimal for NADH oxidation.
In 1986, Krenitsky et al. purified XOR in proteolysed oxidase form (HLXO) 
from post-mortem human liver. Their HLXO showed rates of xanthine 
oxidase activity that were very similar to those of BMXO, in marked 
contrast to our HMXO which has very low xanthine oxidase activity. In 
order to compare substrate specificities of HMXO with those of HLXO and 
BMXO, Km and Vmax values for purine, hypoxanthine, xanthine and 2- 
aminopurine ribonucleoside (2-APR) were determined. The latter reducing 
substrate was particularly chosen because the Km values for HLXO and 
BMXO had been shown to differ greatly. (Krenitsky et al., 1986; Table
9.3). Table 9.3 shows that kinetic parameters for my BMXO preparation 
are broadly similar to those of Krenitsky et al. apart from the relative (to 
xanthine) Vmax for 2-APR, which was very much lower in my preparation. 
Kn and relative Vmax values of HMXO were essentially similar to those of 
my (and Krenitsky’s) BMXO with the notable exception of the Km for 2- 
APR which was markedly lower in the case of HMXO, being much closer 
to that of HLXO.
Virtually all forms of XOR oxidise purine to urate via hypoxanthine and 
xanthine, with the exception of the xanthine oxidase of Clostridium 
cylindrosporum, in which 6,8-dihydroxypurine replaces xanthine
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(Bradshaw & Barker, 1960). Cleere et al. (1975) describe a mathematical 
method for the estimation of intermediates from UV absorption spectra of 
the reaction using isosbestic points. The oxidation of purine to urate by 
HMXOR proceeded via hypoxanthine and xanthine respectively, as it 
does for all mammalian enzymes studied (Cleere et al., 1975). The 
intermediates were found to be hypoxanthine and xanthine which were 
only accumulated in relatively small amounts compared to purine and 
urate. The accumulation of intermediates fits with the hypothesis of 
Jezewska (1973), according to which the intermediates dissociate from 
the enzyme and, once formed, must compete with other substrates.
As discussed previously, human milk was found to have a pH of 6.5, the 
pH at which the rate of NADH oxidation by HMXDH is greatest (Fig. 9.1). 
There is no data on the presence of significant amounts of NAD+ or NADH 
in milk. However as the MFGM is derived from the membrane of the milk 
secreting epithelial cell, the inner side is considered to be cytosolic and 
therefore will contain both, although the overall concentration in milk may 
be below the level of detection. In view of this, if NADH oxidase-derived 
ROS are to have a role in human milk, then it might be expected that, at 
pH 6.5, HMXOR can produce ROS as has been shown at higher pH 
(Sanders et al., 1997). The pH profile of NADH oxidation, superoxide 
production and % flux of electrons to superoxide (Fig. 9.5) shows that, at 
pH 6.5, while the rate of NADH oxidation is higher, the amount and % flux 
of electrons to superoxide is actually less than at higher pH, in the
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presence of 100 pM NADH. This may be explained in terms of the scheme 
for NADH oxidation proposed by Sanders et al. (1997). HMXDH, which 
has a lower Km and a higher Vmax at pH 6.5, will generally be more 
reduced in the presence of higher NADH concentrations than at higher 
pH. These conditions will favour 2 electron transfer to oxygen, generating 
hydrogen peroxide rather than superoxide as indicated in Fig. 9.7 and Fig. 
9.8. Conversely, at very low concentrations of NADH, the percentage flux 
of electrons to superoxide is much higher and more superoxide is 
produced. This difference presumably reflects the dramatic reduction of 
FAD/FADH* midpoint potential at lower pH. At pH 7.5, the midpoint 
potentials for Fe-S I, Fe-S II, FAD/FADH* and FADH’/FADH2 are 
approximately -306, -208, -274 and -222 mV respectively, whereas at pH
6.5 the same potentials are reduced to -286, -188, -217 and -202 mV 
(Porass & Palmer, 1982). At both pH values a two electron reduced 
enzyme would almost certainly have Fe-S II reduced, and the midpoint 
potentials would favour the second electron to reduce Fe-S I rather than 
FAD to FADH*. At pH 7.4 the differences between the midpoint potentials 
of Fe-S I and FAD/FADH* is 66 mV whereas at pH 6.5 this difference is 
reduced to 29 mV. Therefore at pH 6.5 there would be proportionately 
more FADH* containing enzyme than at pH 7.5, capable of reducing 
oxygen to superoxide, and therefore proportionately less FAD containing 
enzyme which is able to be further reduced by NADH and will therefore 
yield hydrogen peroxide.
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The low specific activity of HMXOR toward xanthine and other 
conventional reducing substrates results from the presence of large 
amounts of molybdenum-inactive enzyme (Chapter 9). In fact, this activity 
is of the same order as the specific activity of NADH oxidation, and, 
indeed, at pH 6.5, the rate of NADH oxidation is actually greater than that 
of xanthine oxidation in all samples studied. A workable hypothesis for 
these observations is that the NADH produced from the oxidation of 
xanthine by HMXDH could be reoxidised by molybdenum-inactive enzyme 







H 2 O 2  +  O 2  O 2
Scheme 9.1. The oxidation of xanthine by HMXDH yields ROS in the 
presence of NAD+ or NADH.
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Investigations into the fate of xanthine-derived electrons, showed that, in 
the absence of NAD+, the rate of xanthine oxidation was 13% of that in the 
presence of NAD+. From this, given that in the presence of NAD+ the rate 
of oxygen reduction should be reduced, it is expected that, at least, the 
remaining 87% of xanthine-derived electrons, in the presence of NAD+, 
would reduce NAD+, producing NADH. However, NADH production 
corresponded to only 71% and 44% of the xanthine-derived electrons at 
pH 7.4 and pH 6.5 respectively (Table 9.5).
At pH 6.5, in the presence of low NAD+ concentrations no NADH 
production was observed showing that 100% of xanthine derived 
electrons are therefore reducing oxygen. These discrepancies could be 
explained if a large proportion of NADH that is produced is reoxidised 
according to Scheme 9.1. At the highest NAD+ concentration, production 
of NADH was observed which after considerable turnover was seen to be 
oxidised (Fig 9.10). At higher NAD+ concentrations, NADH oxidation is 
inhibited by NAD+, as described by Sanders et al. (1997), allowing the 
accumulation of NADH. As the xanthine concentration depletes, the rate 
of production of NADH will fall, and under these conditions the relatively 
faster rate of NADH oxidation accounts for the loss of NADH.
The electrons that are reducing oxygen could either produce superoxide 
or hydrogen peroxide. There was an increase in rate of superoxide
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production as increasing concentrations of NAD+ are added to HMXDH in 
the presence of xanthine, as shown in Fig. 9.11. At low NAD+ 
concentrations a large increase in superoxide production is observed 
whereas at higher NAD+ concentrations rate of superoxide production 
decreases. This appears to be analogous to the results with NADH (Fig. 
9.7) where at low NAD+ concentrations a large proportion of superoxide is 
produced, which decreases as the NAD+ concentration increases. A 
similar finding was observed by Nishino et al. (1989 a) where addition of 
NAD+ or 3-aminopyridine adenine dinucleotide, a non-reducible analogue, 
dramatically reduced the percent of superoxide produced by XDH in 
turnover with xanthine. This compound was found to stabilise FADH* 
(Schopfer et al., 1988), and these workers proposed that the superoxide 
produced by reaction of oxygen with FADH* may be sufficiently hindered 
in leaving the flavin that it serves as an electron acceptor for a second 
oxidation reaction.
This finding that NADH is recycled by XDH in turnover with xanthine was 
not observed by Nishino et al. (1989 a.). These workers however used 
enzyme of very high molybdenum content («75%), performed the assay at 
a much higher pH of 7.8 and used much higher concentrations of NAD+. A 
pH of 7.8 would lead to lower rates of NADH reoxidation and the higher 
amounts of NAD+ would cause appreciable inhibition of NADH oxidation 
compared with my system. Most importantly the higher molybdenum 
centre activity of their preparation would mean that most enzyme
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molecules would undergo reduction by xanthine and therefore decrease 
the amount of enzyme that is able to be reduced by NADH under these 
conditions.
The proposed scheme (Scheme 9.1) is therefore unique to preparations of 
enzyme that contain significant amounts of molybdenum-inactive XOR. 
Although the rate of production of superoxide from this scheme is still 
lower than that shown by high activity XO, it does allow the production of 
ROS from xanthine in the presence of low concentrations of NAD+ by 
HMXOR in the physiologically relevant dehydrogenase form. It is worth 
noting that at high concentrations of xanthine, it has been shown that 
oxygen is converted to superoxide very inefficiently by XOR (Fridovich, 
1970; Powell PhD Thesis 1995). This is because the molybdenum active 
molecules in the oxidase form will become reduced by 6 electrons, 
favouring 2 electron reduction of oxygen to hydrogen peroxide (Nishino et 
al., 1989 a, Hille, 1994). The proposed scheme allows the efficient 
production of superoxide even from high concentrations of xanthine, at 
low concentrations of NAD+. In the cell, however, where NAD+ 
concentrations are 400-500 pM (Tischler et al., 1977), proportionately 
more hydrogen peroxide will be produced.
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10 Molybdenum Centre Deficiencies
10.1 Introduction
In many respects HMXOR is similar to BMXOR and enzyme from other 
sources, with the exception of the very low specific activity toward 
xanthine and other purine substrates. NADH oxidase activity has been 
shown to be comparable with that from other sources (Abadeh et al., 
1992; Sanders et al., 1997). Xanthine and all other reducing substrates, 
apart from NADH, are known to be oxidised at the molybdenum domain 
(Hille, 1994), whereas NADH acts at the FAD site (Nishino et al., 1989 b; 
Nakamura 1991). It has been known for many years that purified XOR 
preparations can contain significant percentages of molybdenum-inactive 
enzyme (Morell, 1952; Ventom et al., 1988; Gardlik et al., 1987). In the 
present work, preparations of BMXOR showed activities toward xanthine 
similar to literature values, whereas those of HMXOR, prepared by 
essentially identical procedures, were very low, representing only 
approximately 5 - 10% of the activity of BMXOR (Chapter 9). These 
observations, coupled with the low specific xanthine oxidase activity 
observed in human milk, led us to the conclusion that our inactive 
HMXOR was not simply an artefact of purification and that the molecular 
basis for its inactivity merited investigation.
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It is well established that BMXOR preparations commonly contain 
demolybdo enzyme, lacking Moco. Accordingly, both colourimetric and 
mass spectroscopic determinations of molybdenum of the low activity 
HMXOR and the relatively higher activity BMXOR preparations were 
undertaken and the possibility of a lack of Moco was also investigated.
Desulpho enzyme, in which the essential Mo=S group is replaced by a 
catalytically-inactive Mo=0 group, is also known to be a natural 
component of BMXOR preparations (Nishino et al., 1982; Ikegami & 
Nishino, 1986). Desulpho enzyme can also be generated in vitro. 
Treatment of active XOR with cyanide causes complete inactivation 
resulting in the essential sulphur being released as thiocyanate (Massey 
& Edmondson, 1970), the likely mechanism for this is shown in Scheme
10.1 (Fish et al., 1990).
Scheme 10.1. The inactivation of XOR by removal of the catalytically 
essential molybdenum-sulphur by cyanide.
This process can be reversed by treatment with sulphide, causing 
reincorporation of sulphur at the molybdenum site (Massey & Edmondson 
1970; Nishino et al., 1982). In the present work, the possible presence of
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desulpho enzyme in our HMXOR preparations was investigated by 
attempted resulphuration under reducing conditions with sodium sulphide, 
methyl viologen and sodium dithionite.
10.2 Materials and Methods
10.2.1 Colourimetric molybdenum determinations
Colourimetric molybdenum determination was a scaled down version of 
the method of Hart et al. (1970). Known amounts of XOR, containing 
approximately 10 pmoles of molybdenum in 50-100  pi, were wet ashed in 
10 ml borosilicate glass sample tubes by adding HCI0 4:H2S04 (2:3 v/v) 
(50pl) and heating the open tubes to 260 °C over 3 h, after which all 
samples became colourless. The samples were cooled and 5M HCI (1.5 
ml) was added to each tube, which were then, and subsequently after 
each addition, stoppered and mixed. FeS04 [FeS04.7H20  (1 g) in H20  (20 
ml) acidified by addition of conc. H2S04 (0.4 ml)] (50 pi) and 33% (w/v) 
Nal in H20  (50 pi) were added and, after 10 min, the brown colour was 
discharged by sequential additions of 2.5% (w/v) Na2S 03 in H20  (10 pi). 
Then 10% (w/v) thiourea in H20 (200 pi), 43% (w/v) L(+)tartaric acid in H20 
(50 pi) and dithiol reagent [0.2% (w/v) 3,4-dimercaptotoluene in 1 % (w/v) 
NaOH with 1.4% (v/v) mercaptoacetic acid added] (200 pi) were added 
and the tubes were thoroughly mixed by inversion 100 times and left for
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30 min. Amyl acetate (200 pi) was added and again the samples were 
thoroughly mixed by 100 inversions and left until the amyl acetate had 
separated. The amyl acetate was removed and centrifuged to separate 
any remaining aqueous layer and the spectra were recorded.
Molybdenum contents were calculated by using the difference in 
absorbance between 680 and 540 nm. Standards of (NH4)Mo7024-4H20  
and Mo0 3 were carried through the process to provide an extinction 
coefficient and the molybdenum contents of blanks and standards were 
calculated by using this.
10.2.2 Mass spectroscopy molybdenum estimations
Mass spectroscopy was kindly carried out by Mr P. Turner of Micromass 
Ltd. Manchester. Samples of XOR, Mo03 standard and blanks were wet- 
ashed in conc. HCIO4/H2SO4 (70:30) by heating in a block to 260°C for 3 
h. The samples were then diluted ( 1 - 1 0  ppb Mo) in 5% nitric and 
Inductively Coupled Plasma Mass Spectroscopy (ICP-MS) was performed 
on the samples. The results were calculated against the standard peak 
areas for each of the molybdenum isotopes with molecular masses of 92, 
94, 95, 96 and 100.
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10.2.3 Molybdenum cofactor analyses
The method for the extraction and quantification of molybdopterin is 
based on the method of Frunzke (1993), where liberated cofactor is 
modified by carboxamidomethylation by reaction with iodoacetamide to 
yield di-carboxamidomethyl molybdenum cofactor (di-cam Moco) and 
quantified by HPLC. XOR, 0.2 - 1 mg, in 50 mM Bicine, pH 8.3, (0.5 ml), 
was placed in an anaerobic box and left to equilibrate for 1 h. To each 
sample, 250 mM anaerobic sodium dithionite (20 pi) and 500 mM 
anaerobic iodoacetamide (20 pi) were added and mixed before addition of 
the solution to anaerobic guanidinium hydrochloride to make a final 
concentration of 8M. The samples were wrapped in foil and incubated at 
room temperature for approximately 18 h in the anaerobic box. 40% (w/v) 
ammonium sulphate was added to each sample, the stoppered sample 
tubes were taken out of the anaerobic box and mixed at 4°C by rotation 
for 30 min before centrifugation (13000g, 30 min) at 4°C. The supernatant 
was applied to a Sep-Pak tC18 Cartridge (Waters) washed with H20  (3 
ml) and eluted in methanol (3 ml) at a flow rate of 1 ml/minute. The 
samples were evaporated to dryness in a rotary evaporator, redissolved in 
H20  (500pl), and injected onto a vydac C18 10 p reversed phase HPLC 
column and chromatographed isocratically with 0.1M ammonium acetate 
as the mobile phase at 1 ml/min in a Waters HPLC system. Detection was 
using a Waters multiwavelength detector at 280 and 367nm and peak 
heights were used to compare samples (Johnson et al., 1990).
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10.2.4 Inactivation of HMXOR by desulphuration
HMXOR in 50 mM Na Bicine, pH 8.3, was inactivated by incubation with 
KCN. To a solution of HMXOR, KCN was added to a final concentration of 
10 mM (stock 100 mM KCN in 50 mM NaOH) and incubated at 37°C. 
Activity was followed by taking aliquots of the solution and assaying for 
xanthine oxidase activity (Section 3.2.3). When no activity was observed, 
usually after 2 h, the sample was gel filtered using a G25 PD10 column 
(Pharmacia).
10.2.5 Resulphuration of HMXOR
HMXOR, (0.5 mg) in 50 mM MOPS, pH 7.3, (1 ml) was placed in an 
anaerobic box, (<5 PPM 0 2), and allowed to equilibrate for 1 h. After 
equilibration, anaerobic methyl viologen and sodium sulphide were added 
to final concentrations of 0.2 mM and 2 mM respectively. The solution was 
then titrated with aliquots of 1 mM sodium dithionite (5 jul) until a faint blue 
colour was observed upon reduction of the methyl viologen. The enzyme 
was then incubated at room temperature and regular aliquots were 
removed, gel filtered through a G25 PD10 column (Pharmacia), taken out 




10.3.1 Colourimetric molybdenum estimations
The spectra of XOR samples were determined and the samples were 
appropriately diluted for the estimation of molybdenum. The spectra of the 
molybdenum dimercaptotoluene extracts were taken (Fig 10.1) and used 
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Fig. 10.1. Spectra of molybdenum dimercaptotoluene amyl acetate 
extracts. Spectra shown are triplicates of standards (10 pmoles Mo); 
upper spectra, and blanks; lower spectra.
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The results are shown in Table 10.1, where molybdenum content is 








BMXOR1 0.63 ± 0.04 0.61 ±0.02
BMXOR 2 0.78 ± 0.02
BMXOR 3 0.59 ± 0.02
BMXOR 4 demolybdo 0.22 ± 0.01
BMXOR 5 demolybdo 0.25 ±0.01.
HMXOR1 0.03 ± 0.00 0.06 ± 0.01
HMXOR 2 0.04 ± 0.01
HMXOR 3 0.04 ± 0.01
HMXOR 4 0.03 ± 0.01
HMXOR 5 0.05 ± 0.04
HMXOR 6 0.04 ± 0.01
HMXOR 7 0.02 ± 0.02
HMXOR 8 0.04 ± 0.01
Table 10.1. Content of molybdenum in samples of HMXOR and 
BMXOR. Molybdenum contents were determined colourimetrically 
(Section 10.2.1) and by using mass spectroscopy (Section 10.2.2). 
Molybdenum contents are expressed as a fraction of XOR monomer.
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The analyses show that the molybdenum content of HMXOR varied 
between 0.02 and 0.05, with a mean value for 8 samples of 0.038 ± 0.009 
Mo/XO. BMXOR purified by myself from local milk gave a value of 0.59 ± 
0.02 Mo/XO. Commercially-available BMXOR gave a similar value of 0.63 
± 0.04 Mo/XO and molybdenum-enriched BMXOR from folate affinity 
chromatography (Section 4.3.5) contained 0.78 ± 0.02 Mo/XO. In two 
separate preparations of demolybdo BMXOR using folate affinity 
chromatography chromatography contents of 0.22 ± 0.01 and 0.25 ± 0.01 
Mo/XO were obtained.
10.3.2 Mass spectroscopy molybdenum estimations
The results, in Table 10.1, show that the estimations of molybdenum by 
mass spectroscopy gave very similar figures to those of the colourimetric 
analyses.
10.3.3 Molybdenum cofactor estimation
The inherent instability of the cofactor in air and light made exact 
quantification difficult and large losses in the cofactor were encountered. 
Between the two estimations, a 7 fold difference in yield was observed 
and the yield of di-cam Moco was relatively lower at higher concentrations 
of XOR. The Moco content of BMXOR in both analyses was assumed to
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be 100% and the relative amount in HMXOR was calculated. Table 10.2 
shows that the cofactor content of HMXOR was approximately 25% that of 
BMXOR, but because of large errors it is difficult to be fully confident of 
this value.
Analysis Enzyme Sample Peak height / mg % BMXOR
1 BMXOR1 0.0018 + 0.0006 100 ±30
HMXOR1 0.0005 ± 0.0002 27 ±31
2 BMXOR1 0.0132 ±0.0031 100 ±23
HMXOR1 0.0031 25
Table 10.2. Molybdenum cofactor content of HMXOR and BMXOR.
The molybdenum cofactor was estimated by derivatisation and 
measurement of the 280nm peak height from HPLC (Section 10.2.3). The 
peak heights are expressed per mg XOR used per assay. To enable 
comparison between the two analyses, the peak heights / mg XOR are 
expressed as a percentage of BMXOR.
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10.3.4 Estimations of inactive molybdenum-containing forms in 
HMXOR and BMXOR, based on xanthine oxidase activities and 
molybdenum contents.
The specific xanthine oxidase activities of HMXOR and BMXOR were 
normalised to 100% Mo content and, using a theoretical maximum AFR of 
210 (Massey et al., 1970), the percentages of inactive molybdenum- 
containing enzyme were calculated. Table 10.3 shows comparable 
specific activities for HMXOR and BMXOR, suggesting similarly high 
contents (50 - 60%) of desulpho enzyme.
HMXOR1 BMXOR 3
Xanthine oxidase activity 
(nmol/min/mg)
87.2 ±4.4 1377.0 ±23.5
Mo/FAD 0.04 ± 0.00 0.59 ±0.02
Xanthine oxidase activity 
(nmol/min/mg 100% Mo)
2180 + 110 2334 ± 40
% desulpho 59 ± 2 56 ±1
Table. 10.3. Molybdenum-specific activities of HMXOR and BMXOR.
The total xanthine oxidase activity of samples of HMXOR and BMXOR 
were assayed and, using the known molybdenum contents, converted into 
specific activities per mg of molybdenum-containing enzyme. Assuming a 
fully functional AFR of 210, the percentage of inactive molybdenum was 
calculated.
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10.3.5 Resulphuration of HMXOR
In view of the indications (Section 10.3.4) that HMXOR, in addition to 
containing a very high percentage of demolybdo enzyme, also has high 
contents of desulpho form, in vitro activation of the latter was attempted. 
HMXOR and HMXOR that had been previously-inactivated by cyanide 
treatment were separately resulphurated. Specific xanthine oxidase 
activities were determined (Section 3.2.3) before and after inactivation 
and after resulphuration (Table 10.4). Also the specific xanthine oxidase 
activity of HMXOR was monitored during the resulphuration process 
(Figure 10.2). Cyanide treatment of HMXOR caused total loss of activity 
after 2 h incubation. Both the active and cyanide-inactivated HMXOR 
samples regained more than their original activity, indicating that the 
original HMXOR sample contained desulpho enzyme (see Discussion)
Sample Activity expressed as % of 
HMXOR
HMXOR 100%±0%
HMXOR after cyanide-inactivation 0% ± 0%
HMXOR after resulphuration 147% ±3%
Cyanide-inactivated HMXOR after 
resulphuration
127% ±2%
Table 10.4. The activities of cyanide-inactivated and resulphurated 












Fig. 10.2. Resulphuration of active HMXOR. HMXOR was resulphurated 
and the process was monitored by measuring xanthine oxidase activity 
throughout the timecourse. The activity is expressed as a percentage of 
that of the initial enzyme. Error bars relate to standard errors with n=3.
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10.4 Discussion
HMXOR was shown to have a molybdenum deficiency of approximately 
95%, BMXOR had a deficiency 40%; a not unusual value, as similar 
molybdenum deficiencies have been reported in many samples of 
BMXOR purified by a variety of methods (Hart et al., 1970; Avis et al., 
1956 a). The low molybdenum content of HMXOR is however highly 
unusual, such values only having been previously reported in samples of 
fractionated demolybdo BMXOR (Gardlik etal., 1987; Ventom etal., 1988) 
or in XOR derived from specially tungsten-fed rats (Johnson et al., 1974). 
The estimation of the molybdenum cofactor gave lower values for HMXOR 
than it did for BMXOR, indicating that, like demolybdo enzyme from other 
sources, HMXOR is also deficient in the molybdenum cofactor (Gardlik et 
al., 1987; Ventom et al., 1988). Unfortunately precise quantification was 
not possible due to the large errors in the assay.
Molybdenum deficiencies of HMXOR and BMXOR did not fully account for 
their specific xanthine oxidase activities, suggesting that a proportion of 
both enzymes contained molybdenum in the desulpho inactive form. This 
was confirmed, in the case of HMXOR, by the resulphuration of both 
active and cyanide-treated enzyme. Resulphuration of the cyanide-treated 
HMXOR achieved a specific activity of 127% that of the original enzyme 
while the specific activity of the untreated HMXOR increased to 147% of 
the original. Previously, it has been reported that upon the resulphuration
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of cyanide-inactivated enzyme the specific activity will only increase to 
half of the theoretical activity maximum (Nishino et al., 1982). Therefore a 
27% increase would mean that the total theoretical maximum was 254% of 
the original. Therefore the calculated active enzyme content would be 
39% (100%/254%) in the original sample. Similarly, the active enzyme 
content of the untreated enzyme is calculated to be 34% (100%/294%). 
The difference between the two figures could result partly from slight 
overall inactivation of the enzyme during the cyanide-inactivation process. 
These values for desulpho content are in reasonable agreement with 




11.1 Purification of XOR
The preparation of XOR from bovine milk was found to yield 
approximately 24 mg XOR per I milk, comparable to amounts (19 mg/l), 
previously reported, (Hunt & Massey, 1992). Using an essentially identical 
preparation procedure, from fresh human milk, similar yields were 
obtained. However, the logistics of human milk collection dictated the use 
of frozen milk, from which yields of enzyme were initially only 
approximately 5 mg XOR per I milk, four fold lower than from fresh milk. 
The problem was addressed and improved conditions, involving addition 
of DTT, were developed that facilitated release of XOR from the 
membrane. The modified preparation yielded 21 mg HMXOR per I frozen 
milk; amounts comparable to those from fresh human or bovine milk.
The pterin oxidase activity in bovine milk was found to be approximately 
27800 nmol min'1 I'1 whereas that in thawed human milk was 23 fold lower 
at approximately 1200 nmol min'1 I'1. Purified BMXOR and HMXOR were 
found to have specific xanthine oxidase activities in the respective ranges 
of 1200 -1500 nmol min'1 mg'1 and 30 -1 1 0  nmol min'1 mg'1 which, using 
average values, represents a 20 fold lower specific activity of HMXOR 
compared with BMXOR. These values of specific activity were a little
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higher than those (1060 nmol min'1 mg'1 and 24 nmol min'1 mg'1) 
previously reported in our lab for BMXOR and HMXOR (Abadeh et al.} 
1992), but nevertheless similar, in the case of BMXOR, to the value (1480 
nmol min'1 mg'1) reported by Hunt and Massey (1992). Sarnesto et al. 
(1996) reported, on the basis of ELISA and enzyme activity assay, that 
the XOR in human milk had a specific activity of 600 nmol min'1 mg'1; a 
value considerably higher than that obtained in the present study for 
purified enzyme. However, in Sarnesto et al. assays were carried out at 
37°C, whereas in this study they were done at 25 °C.
The above comparisons relate to the question as to whether the very low 
xanthine (or pterin) oxidase activity in purified HMXOR reflects loss of 
activity during the preparation procedure. The occurrence of such 
inactivation is not supported by the data. Thus, based on similar yields of 
purified enzyme from human and bovine milk, the ratios of HMXOR to 
BMXOR specific activities in whole milk and purified enzymes are 
comparable. Moreover, repeated freeze thawing was shown not to 
decrease the specific activity of HMXOR (data not shown). From this I 
concluded that the enzyme purified from human milk has not been 
significantly inactivated by freezing or during the preparation, and 
therefore that the low specific activity of purified HMXOR represents that 
in vivo. Concerning the data of Sarnesto et al. (1996), after adjustment for 
assay temperatures, their specific activity for XOR in fresh human milk is
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approximately twice that obtained by me for purified enzyme. A difference 
that could well reflect different samples of breast milk.
The low specific activity of XOR in milk is not unique in human tissue. 
Similarly low specific activity XOR was identified in preliminary 
purifications from human heart (Abadeh et al., 1993) and the specific 
activity shown by ELISA and activity assays in cultured human epithelial 
cells was 45 nmol min*1 mg*1 (Page et al., 1998). Moreover, low activity 
toward conventional reducing substrates in other whole human tissues 
also indicates similarities with the human milk enzyme (Parks & Granger, 
1986). Human liver and intestine appear to be exceptional in showing high 
catalytic rates toward conventional reducing substrates (Parks & Granger, 
1986), suggesting that XOR in these tissues has relatively high specific 
activity. This idea is supported by the specific activity (1800 nmol min*1 
mg*1) of XOR purified from post-mortem human liver (Krenitsky et al., 
1986) and by values quoted for human liver (2700 nmol min*1 mg*1) and 
intestine (3000 nmol min'1 mg*1) by Sarnesto et al. (1996) on the basis of 
ELISA and activity assays of whole tissue homogenates.
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11.2 Inactive forms of HMXOR
In this study, the molecular basis for the low specific activity of HMXOR 
was addressed. Abadeh et al. (1992) noted that, whereas the xanthine 
oxidase activities of HMXOR and BMXOR differed by 50 fold, their 
activities toward NADH as reducing substrate were similar; facts that they 
attributed to the presence of large amounts of molybdenum-inactive 
enzyme in their HMXOR preparation. Enzyme forms with an inactive 
molybdenum centre are indeed well known. Desulpho-XOR lacks a 
catalytically essential Mo=S group, replaced by Mo=0, while demolybdo- 
XOR lacks molybdenum and possibly also its cofactor. Both of these 
inactive forms have been shown to be present in preparations of enzyme 
from a variety of sources.
The present study re-evaluated the molecular basis for the low activity of 
HMXOR initially by estimating the molybdenum contents of different 
samples of HMXOR, one of which was a specially-prepared “big batch” on 
which several different assays could be performed. Molybdenum contents 
were determined both by using the colourimetric method of Hart et al. 
(1970) and by ICP-MS. The two methods produced comparable results 
and showed that, in HMXOR, greater than 95% of the molybdenum is 
absent, compared to an approximate deficiency of 37% for BMXOR.
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The presence of such large amounts of demolybdo-enzyme was shown to 
account for most, but not all of the low activity of HMXOR. The content of 
the molybdenum-inactive desulpho-enzyme was therefore investigated. 
Resulphuration of HMXOR showed an increase in specific activity of 47%. 
On this basis, the desulpho-content of molybdenum-containing enzyme 
was estimated to be 61 %, a value that fits well with the estimation of 59% 
from known molybdenum and activity data. These values are further 
supported by EPR data on my “big batch” HMXOR sample (Bray, personal 
communication).
The presence of the molybdenum cofactor (Moco), in HMXOR was also 
investigated as previous reports have indicated its absence in demolybdo- 
BMXOR (Gardlik et al., 1987; Ventom et al., 1988). Moco was found to be 
of the order of 75% lower in HMXOR than in BMXOR, However, because 
of large inaccuracies in the assay procedure I was unable to determine 
the precise content for either enzyme.
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11.3 Spectral analyses
UV-Visible spectroscopy revealed significant differences between 
HMXOR and BMXOR, suggesting differences in their respective 
chromophores. Given that the former has a very much lower content of 
molybdenum, and possibly cofactor, it was initially attractive to attribute 
differences on this basis. However, quantification of the extinction 
coefficients, based on FAD estimations, allowed an accurate difference 
spectrum between HMXOR and BMXOR to be obtained. This difference 
spectrum was found to be remarkably similar to the spectrum of Fe-S 
protein II from Azobacter vinelandii (Shethna et a/., 1968) and of deflavo 
BMXOR (Komai et al., 1969), suggesting that spectral differences 
between HMXOR and BMXOR could be largely attributable to a relative 
lack of Fe-S in HMXOR. Comparison of €450 values led to estimated 
deficiencies in Fe-S centre contents of 4 % and 30 % respectively for 
BMXOR and HMXOR, relative to molar equivalence with FAD. 
Confirmation of these estimated Fe-S deficiencies was obtained by 
computed addition of the spectra of FAD and BMXOR so as to reproduce 
the calculated Fe-S/FAD ratio of HMXOR, assuming negligible 
contribution to the spectra of molybdenum or Moco. By these means, the 
HMXOR visible spectrum was simulated with remarkable accuracy.
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CD Spectroscopy was carried out on HMXOR, BMXOR and a sample of 
demolybdo-BMXOR, prepared by fractionation of BMXOR on a folate- 
affinity column. It is known that, in CD spectra of XOR, the main Cotton 
effects are largely attributable to Fe-S, with only small contributions from 
FAD, molybdenum and Moco (Bayer et al., 1971; Komai et al., 1969). 
From CD spectra, matched on a molar basis, it was seen that HMXOR 
and demolybdo-BMXOR samples have significantly smaller Cotton effects 
than does BMXOR. Normalisation of these spectra for Fe-S content, as 
determined above, led to spectra very similar in form and intensity, 
confirming calculations based on the UV-visible absorbance data.
CD spectra, both before and after Fe-S normalisation, showed relatively 
small differences below 350 nm. Previously, these have been attributed to 
differences in Moco content (Gardlik et al., 1987); an explanation 
consistent with the findings of the present study. After normalisation for 
Fe-S, a HMXOR - BMXOR difference spectrum was obtained which 
showed negative and positive cotton effects at 500 nm and 575 nm 
respectively. This difference spectra was remarkably similar in form to that 
of Molv - Movl for BMXOR (Ryan et al., 1995), suggesting that my 
difference spectrum relates to the CD spectrum of Movl in XOR.
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11.4 Fe-S deficiency
Gardlik et al. (1987), working with demolybdo-BMXOR, observed a lack of 
Fe-S, which, on the basis of EPR parameters, they attributed specifically 
to a lack of the Fe-S I centre and, to some extent, a replacement of this 
centre by a new Fe-S centre. Working with my HMXOR, Bray (personal 
communication) has arrived at similar conclusions. As a significant Fe-S 
deficiency has not been noted in any other system, this is of great 
interest. In the present studies, large deficiencies of Fe-S were observed 
not only with HMXOR, but also with demolybdo-BMXOR, suggesting a 
possible relationship between lack of Fe-S and molybdenum. The 
distance between the molybdenum and Fe-S I in BMXOR has been 
estimated, by magnetic coupling, to be 8 -1 4  A, considerably closer than 
any other two pairs of redox centres (Lowe & Bray, 1978). In our 
laboratory, efforts are underway to model the structure of HMXOR using 
co-ordinates derived for the related enzyme, aldehyde oxidoreductase 
(Romao et al., 1995). Much of this structure has been modelled and, as 
shown in Fig 11.1 (Pearson, personal communication), Fe-S I and Moco 
are contiguous, with an Fe-S l-associated cysteine residue (Cys 139) in 
particular, being located very close to Moco.
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Fig. 11.1. The molybdenum and iron sulphur I centres in HXO.
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This intimate contact between Fe-S I and Moco adds credence to a link in 
deficiencies of these cofactors and to the possibility that the absence of 
Moco is able to alter the Fe-S I centre in such a way as to change its EPR 
parameters. The present treatment of the data may imply that Fe-S 
deficiency or alteration is a consequence of Moco deficiency. It is, 
however, conceivable, on the available evidence, that the reverse applies, 
in that changes in Fe-S lead to the absence of Moco.
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11.5 Substrate specificities
Other than the low specific activity, largely attributed to the lack of 
molybdenum, the possibility remained that HMXOR was essentially 
identical to human liver XOR. Krenitsky et al. (1986) compared the wide 
substrate specificities of HLXOR and BMXOR and observed significant 
kinetic differences between the two enzymes. In the present work, these 
assays were repeated with HMXOR and BMXOR, using xanthine, 
hypoxanthine purine and 2-APR. Substrate specificity reflects substrate 
binding sites on XOR and can give information regarding differences 
between HMXOR and BMXOR, irrespective of different activity levels 
dependent on molybdenum content. In my hands the relative activities of 
BMXOR toward the above substrates were shown to be generally similar 
to those found by Krenitsky et al. (1986). HMXOR showed significant 
differences from BMXOR, and was found to be more similar to HLXOR 
based on the data of Krenitsky et al. (1986).
The primary structure of HMXOR is currently being determined in our 
laboratory and, although still lacking 200 of 1300 residues (Briggs & 
Pearson, unpublished data), it is very much closer to that of HLXOR 
(Ichida et al., 1993) than to that of BMXOR (Berglund et al., 1996) (see 
Appendix Section 12.3). The presently-described specificity data are 
clearly consistent with this.
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11.6 Molecular weight of HMXOR
Abadeh et al. (1992), using gel filtration, reported the molecular weight of 
HMXOR to be slightly higher than that of BMXOR, and, in our laboratory, 
HMXOR has consistently shown a lower mobility on SDS-PAGE compared 
with BMXOR. The molecular weights of HMXOR and HLXOR have been 
quoted as approximately 300 kDa on the basis of gel filtration and native- 
PAGE (Krenitsky et al 1986; Sarnesto et al 1996). However in these 
studies human enzyme was not compared directly with that from other 
sources. In the present work, SDS-PAGE, gel filtration, dynamic light 
scattering (DLS) and native-PAGE all demonstrated a consistently higher 
molecular weight of HMXOR compared with BMXOR. However, the 
calculated molecular weights from the published sequences of BMXOR 
(Berglund et al., 1996) and HLXOR (Ichida et al., 1993), which is 
essentially identical to HMXOR (see Section 11.5), are very similar; a 
conclusion confirmed in the cases of HMXOR and BMXOR by MALDI- 
TOF MS data (Bray, personal communication). This indicates that the 
differences in apparent molecular weight reported here and previously 
result from factors other than mass. Gel filtration, DLS and native-PAGE 
are all susceptible to the tertiary structure of proteins, whereby a less 
spherical and compact enzyme appears to have a higher molecular 
weight. As a consequence of a lack of molybdenum and Moco, it is 
conceivable that HMXOR is partially unfolded and therefore appears,
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when using the techniques described above, to be larger. However, as the 
bovine enzyme used in this study also contained significant quantities of 
demolybdo-enzyme, one may expect these techniques to reveal two, 
albeit close, components of different molecular weights. This was not 
observed. An apparent difference in mobility on SDS-PAGE cannot be 
explained in this way, as the proteins are completely denatured under 
these conditions. This technique is however susceptible to the primary 
structure of proteins. For example, mobility can be affected by a very large 
charge or proline-rich regions. The primary structures of BMXOR and 
HLXOR, which is essentially identical to the known sequence of HMXOR, 
contain very similar numbers of charged residues. However 9 out of 32 of 
the residues 193 - 225 of BMXOR are prolines, which correspond to the 
loop region between the Fe-S and FAD domains (Sato et al., 1995). This 
region is similar in HLXOR, yet a full comparison of the amino acid 
sequence of HMXOR awaits data for the first 200 amino acids, and it will 
be interesting to compare the sequence of HMXOR in this region.
177
11.7 Aggregation of HMXOR
Differences in the stabilities of HLXOR and BMXOR after freezing and 
storage were noted by Krenitsky et al. (1986), and Abadeh et al. (1992) 
observed that HMXOR aggregated under these conditions. Demolybdo- 
BMXOR was found to be more susceptible to denaturation than active 
BMXOR in the presence of salicylate (Bergel & Bray, 1956). In the present 
work, it was shown that repeated freeze-thawing of HMXOR did not 
significantly affect its specific activity, although it was seen to increase the 
amount of aggregation, as judged by increased loss of protein after 
centrifugation (data not shown). This aggregation was much more 
pronounced than for BMXOR and not attributable to denaturation. The 
nature of this aggregation remains unclear. It is, like that of many other 
proteins, concentration dependent. It can be prevented and, once 
initiated, partially reversed by addition of low concentrations of NaCI, 
suggesting that the aggregation is electrostatic in nature. DTT was shown 
to dissolve the centrifugate from aggregated HMXOR and to disaggregate 
it in a time-dependant manner. The time course of this process was 
similar to that involved in the XO to XDH conversion, indicating that 
reduction of disulphides is somehow involved in disaggregation.
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11.8 Heparin affinity
XOR has been shown to bind to heparin-agarose. This binding has been 
shown to be electrostatic in nature, and to involve lysine residues of XOR. 
Fukushima et al. (1995) isolated heparin-binding peptides, proteolytically- 
derived from HMXOR, identified them by amino acid sequencing and 
found them to contain lysine residues. My analysis of the data is that the 
equivalent peptides in aldehyde oxidoreductase are exposed on the 
exterior surface of the enzyme. Adachi et al. (1993) demonstrated that 
HMXOR will bind to endothelial cells in a manner analogous to its binding 
to heparin-agarose and proposed that this binding is via membrane- 
associated glycosaminoglycans. I have shown that DTT-reduced HMXOR 
has a lower affinity for heparin than does untreated enzyme. These 
differences do not simply reflect the presence of oxidase or 
dehydrogenase forms, because DTT-treatment can lower the affinity of 
proteolysed oxidase enzyme to that of the non-proteolysed 
dehydrogenase form. It is worthy of note that circulating XOR is most 
likely to be in the oxidase form and so best suited to bind to endothelial 
cell membranes, which may then be injured by XOR-generated ROS (Koiij 
et al., 1994).
In many respects differences in heparin affinity between BMXOR and 
HMXOR follow the same pattern as aggregation. I have shown a 
considerable species difference in the tendencies of XOR to aggregate,
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HMXOR has a considerably higher affinity for heparin than does BMXOR. 
In fact, at pH 7.4, BMXOR will not bind to heparin-agarose beads (Radi et 
al., 1997). Aggregation of HMXOR can be reduced by addition of DTT, as 
can heparin affinity, and both aggregation and heparin binding can be 
reduced by NaCI. Clearly, both aggregation and heparin-binding 
properties are dependant on conformation, itself subject to modification by 
sulphydryl oxidation. It is conceivable that the increased aggregation and 
heparin-binding we observe of HMXOR compared with BMXOR results of 
an increased exposure of a positively-charged region. Such a region 
might not only bind to sulphated glycosaminoglycans, but could also 
facilitate aggregation by binding to its negatively-charged neighbours.
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11.9 Oxidase and dehydrogenase interconversions
The oxidase form of XOR is generally considered to be the source of 
destructive ROS whether in the inflammatory response or in pathological 
states involving l-R (Kooij et al., 1994). While XDH to XO interconversions 
have been well studied for BMXOR and rat liver XOR, very little has been 
reported concerning human XOR. Sanders et al. (1997) demonstrated that 
proteolysis of HMXOR can produce very largely oxidase form enzyme; an 
observation confirmed it the present study. However, there is no 
published information concerning non-proteolysed HMXO, although the 
interconversions of human XOR are generally assumed to be identical to 
those of the well-studied rat liver and bovine milk enzymes. I compared 
the non-proteolytic interconversions of HMXOR and BMXOR and found 
this not to be the case.
The DTT-induced oxidase to dehydrogenase conversions of HMXO and 
BMXO were found to be very similar to each other The reverse 
conversions of BMXDH to BMXO were generally as described in previous 
reports (Nakamura & Yamakazi 1982; Hunt & Massey, 1992) and similar 
to those of the rat liver enzyme (Della Corte & Stirpe, 1971; Waud & 
Rajagopalan 1976 b; Saito, 1987), HMXOR, however was different in that 
HMXDH to HMXO conversion was not only slower but much less 
complete.
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Waud and Rajagopalan (1976 b) described the conversion for the enzyme 
from rat liver with DTDP, which showed that the rapid oxidation of 14 
sulphydryl groups was complete after 20 minutes, whereas the conversion 
was only complete after 270 minutes. These workers concluded that there 
were two phases in the conversion, the oxidation of sulphydryls followed 
by a slower conformational change. Like the rat liver enzyme, DTT- 
reduced HMXOR was found to contain 14 free sulphydryl groups per 
subunit which are rapidly oxidised by DTDP, yet even after 24h incubation 
the oxidase activity only accounted for 64% of the total, compared with a 
value of 98% for BMXOR. The number of free cysteines in a HMXO 
preparation rich in oxidase form (75%) was estimated to be 7.6 ± 1.0 per 
subunit, which gave a difference between fully reduced enzyme of 6 
sulphydryl groups per subunit, similar to the number (7 per subunit) 
quoted for the dehydrogenase to oxidase conversion of BMXOR and rat 
liver XOR (Saito, 1987; Hunt & Massey, 1992). The finding that the same 
number of sulphydryl groups is available for oxidation in HMXOR as in 
enzymes from other sources largely exclude this as a factor in the 
incomplete conversion to HMXO (Saito, 1987). Moreover, the fact that the 
high oxidase enzyme could be obtained through proteolysis indicate that, 
unlike the avian enzyme (Sato et al., 1995), formation of highly oxidase 
form was possible. A remaining explanation is that the conformational 
change required after oxidation of sulphydryl groups is less favoured than 
that for bovine milk and rat liver enzymes.
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11.10 Significance of inactive XOR
The large proportions of demolybdo-XOR in human milk and, by analogy, 
in tissues other than liver and intestine, suggests a physiological 
significance. It is known that purine catabolism is strictly regulated as 
purine biosynthesis is very energy consuming and the majority of purines 
are salvaged. Less active XOR will certainly help in this respect. Inactive 
enzyme may, however, be activated if necessary. Inactive XOR in the liver 
of chickens can be activated as the protein content of the diet is 
increased. Itoh et al., (1978) attributed this activation to desulpho-sulpho 
conversion (see Section 1.4.2); a process for which enzyme-catalysed 
mechanisms have been proposed (Nishino et al., 1983). Page et al. 
(1988) showed that the enzyme in a human mammary epithelial cell line 
has low xanthine oxidase activity, similar to that found in human milk. 
However, upon administration of the inflammatory cytokine interferon y, an 
800% increase in activity was observed, which was shown to result partly 
from an approximately 3-fold post translational activation. The specific 
activity in unstimulated cells was shown by ELISA and activity assays to 
be 45 nmol min'1 mg'1 and therefore would increase to 144 nmol min*1 
mg'1. Even after this increase, the vast majority of the protein must still be 
assumed to be inactive, when comparison is made with BMXOR with a 
specific activity of 1500 nmol min'1 mg'1. Also relevant to these 
discussions are the findings of Brown et al, (1995) who showed that
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xanthine oxidase activity in human milk peaked during the first 15 days 
after birth and fell thereafter; an increase attributable to an increase in 
specific activity, as corresponding changes in XOR protein were not 
observed. The extent of activation observed (maximum rate of 85 nmol 
min'1 mg'1) again places the specific activity increase within the scope of 
the low molybdenum content in my samples of HMXOR and allows a 
desulpho-sulpho conversion to account for their activation.
One ROS-producing activity that is not affected greatly by the form of the 
enzyme or by lack of molybdenum is the NADH oxidase activity, which , 
considering the large amounts of inactive enzyme present in some 
tissues, may have a physiological role. The concentration of cytoplasmic 
NADH is 1pM, whereas NAD+ is 400-500 pM (Tischler et al., 1977). 
During ischemia there is an increase in cytoplasmic levels of NADH, with 
the NAD/NADH ratio decreasing from 700 to 30 (Nishino & Tamura, 
1991). If the same substrate pool is available after ischemia, then the 
cytoplasmic NADH concentration could increase to 13-17 pM. On this 
basis, it has been postulated (Harrison, 1997; Zhang et al., 1998) that 
NADH oxidase activity, triggered by increased NADH concentrations in 
ischemia, may replace or complement the much discussed xanthine 















Scheme 11.1. The mechanism for production of ROS from NADH by 
XOR during ischemia. Modified from Harrison (1997).
My observation that a low molybdenum-active enzyme in the 
dehydrogenase form can very efficiently produce ROS from xanthine 
oxidation, in the presence of low concentrations of NAD+ may also have 
some relevance here. I-R injury has been shown to be greatly reduced by 
administration of specific XOR molybdenum centre inhibitors. During 
ischemia, NADH levels rise, as do the levels of hypoxanthine and 
xanthine, which rapidly decrease during reperfusion (Xia & Zweier, 1995). 
Also during ischemia, the pH of tissues falls to approximately 6.5 (Herman 
et al., 1990), a pH which favours the oxidation of NADH (Fig. 8.1) and the 
proposed recycling back to NAD+. On this basis I propose an alternative 
hypothesis for l-R injury and physiological ROS production in tissues 
containing XOR of low specific activity which accounts for all the above 
observations, does not depend upon a dehydrogenase to oxidase
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conversion and is consistent with blockage of ROS production and l-R 
Injury by molybdenum centre inhibitors. During Ischemia, as described by 
Granger et al. (1981), there is a net catabolism of ATP, producing 
hypoxanthine and xanthine, and as the pH drops these are oxidised by 
XOR producing NADH, which accumulates. Upon reperfusion demolybdo- 
XOR rapidly oxidises NADH, which is replaced at a similar rate by the 
oxidation of xanthine and hypoxanthine. ROS generated from NADH 
oxidation upregulate transcription factors, increase ICAM production and 

























Scheme 11.2. Proposed new mechanism for production of ROS from 
largely demolybdo enzyme.
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A similar scheme is also relevant to cells under normal physiological 
conditions as I have demonstrated that the same recycling mechanism 
can operate, albeit less efficiently, at higher pH. Because all the reducing 
equivalents derive from xanthine this mechanism allows inactivation and 
activation of the molybdenum centre via a sulpho-desulpho switch to 
control the overall rate of ROS production.
Although not explored in the present study, this scheme may also be 
relevant to higher activity enzymes, such as those observed in bovine milk 
and rat liver, which are still 50 - 70% inactive. In situations of non­
saturating substrate concentrations, for example at 0.5 pM xanthine, or a 
considerably higher concentration of a substrate with a correspondingly 
lower Vmax, the xanthine: NADH turnover of the inactive enzyme would be 
sufficiently low as to be comparable to the rate of NADH:NAD+ turnover of 
the inactive enzyme.
This demonstration of the production of ROS from the dehydrogenase 
form of XOR, omits the necessity of the increasingly questionable 
dehydrogenase to oxidase conversions that many of the proposed 
hypotheses of XOR in physiological and pathological conditions depend 




12.1 Sequence alignment of HLXOR and BMXOR.
HLXOR (Ichida etal., 1993); top sequence 
BMXOR (Berglund et a/., 1996); bottom sequence
MTADKLVFFV NGRKWEKNA DPETTLLAYL RRKLGLSGTK LGCGEGGCGA CTVMLSKYDR
★ k  k  k  k  k  k  k ★ ★ ★ ★  ★
MTADELVFFV NGKKWEKNA DPETTLLAYL RRKLGLRGTK LGCGEGGCGA CTVMLSKYDR
LQNKIVHFSA NACLAPICSL HHVAVTTVEG IGSTKTRLHP VQERIAKSHG SQCGFCTPGI
k  k  k  k  k ★ ★ ★ ★  k k k k k k k k  k  k k k k k k k k k k  k k k k k k k k k k  k k k k k k k k k k  k k k k k k k k k k
LQDKIIHFSA NACLAPICTL HHVAVTTVEG IGSTKTRLHP VQERIAKSHG SQCGFCTPGI
VMSMYTLLRN QPEPTMEEIE NAFQGNLCRC TGYRPILQGF RTFARDGGCC GGDGNNPNCC
* * * * * * * * * *  * * * * *  * * * *  * * * * * * * * *  * * * * * * * * * *  * * * *  * * * *  * *  * * * * * * *
VMSMYTLLRN QPEPTVEEIE DAFQGNLCRC TGYRPILQGF RTFAKNGGCC GGNGNNPNCC
MNQKKDHSVS HSPSLFKPEE FTPLDPTQEP IFPPELLRLK DTPRKQLRFE RERVTWIQAS
k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k k k k k k k k  k k k k k k k k k k  k  k  k  k  k  k  k  k  k k k k k k k k k
MNQKKDHTVT LSPSLFNPEE FMPLDPTQEP IFPPELLRLK DVPPKQLRFE GERVTWIQAS
TLKELLDLKA QHPDAKLWG NTEIGIEMKF KNMLFPMIVC PAWIPELNSV EHGPDGISFG
k k k k k k k k k k  ★ ★ ★  k  k  k  k  k  k  k k k k k k k k k k  k  k ★ ★ ★ ★ ★  ★ k k k k k k k k  k  k  k  k  k  k  k  k  k k
TLKELLDLKA QHPEAKLWG NTEIGIEMKF KNQLFPMIIC PAWIPELNAV EHGPEGISFG
AACPLSIVEK TLVDAVAKLP AQKTEVFRGV LEQLRWFAGK QVKSVASVGG NIITASPISD
* * *  * *  * * *  * *  * * * * * *  * * * * * * * * *  * * * * * * * * * *  * * * * * * *  * *  * * * * * * * * * *
AACALSSVEK TLLEAVAKLP TQKTEVFRGV LEQLRWFAGK QVKSVASLGG NIITASPISD
LNPVFMASGA KLTLVSRGTR RTVQMDHTFF PGYRKTLLSP EEILLSIEIP YSREGEYFSA
★ ★ ★ ★ ★ ★ ★ ★ ★  ★ + ★ k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k k k k k k k k k k  k  k  k  k  k  k  k  k
LNPVFMASGT KLTIVSRGTR RTVPMDHTFF PSYRKTLLGP EEILLSIEIP YSREDEFFSA
FKQASRREDD IAKVTSGMRV LFKPGTTEVQ ELALCYGGMA NRTISALKTT QRQLSKLWKE
k k k k k k k k k k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k k k k k k k k k k  k k k k k k k k k  k  k  k  k  k  k  k k
FKQASRREDD IAKVTCGMRV LFQPGSMQVK ELALCYGGMA DRTISALKTT QKQLSKFWNE
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ELLQDVCAGL AEELHLPPDA PGGMVDFRCT LTLSFFFKFY LTVLQKLGQE NLEDKCGKLD
k k k k k k k k k  k  k  k  k ★ k  k  k  k  k  k  k  k  k ★ k k k k k k k k k k  ★ ★ ★ ★  k  k  k  k  k  k  k
KLLQDVCAGL AEELSLSPDA PGGMIEFRRT LTLSFFFKFY LTVLKKLGKD SK DKCGKLD
PTFASATLLF QKDPPADVQL FQEVPKGQSE EDMVGRPLPH LAADMQASGE AVYCDDIPRY
* *  * * * * * *  * *  * * *  * *  * * * * * * * * *  * *  * * * * * * *  * * *  * * * * * *  * * * * * * * * * *
PTYTSATLLF QKHPPANIQL FQEVPNGQSK EDTVGRPLPH LAAAMQASGE AVYCDDIPRY
ENELSLRLVT STRAHAKIKS IDTSEAKKVP GFVCFISADD VPGSNITGIC NDETVFAKDK
k  k  k  k  k  k  k  k  k  k k k k k k k k k k  k  k ★ ★ ★  ★ ★ ★  k  k  k k  k  k  k  k  k  k  k  k  k  k  k  k k k k k k k k k
ENELFLRLVT STRAHAKIKS IDVSEAQKVP GFVCFLSADD IPGSNETGLF NDETVFAKDT
VTCVGHIIGA WADTPEHTQ RAAQGVKITY EELPAIITIE DAIKNNSFYG PELKIEKGDL
k k k k k k k k k k  k k k k k k k k  k  k  k  k  k  k  k  k  k k k k k k k k  k k k k k k k k k k  k k k k k k k k k
VTCVGHIIGA WADTPEHAE RAAHWKVTY EDLPAIITIE DAI KNNSFYG SELKIEKGDL
KKGFSEADNV VSGEIYIGGQ EHFYLETHCT IAVPKGEAGE MELFVSTQNT MKTQSFVAKM
k k k k k k k k k k  k  k  k  k  k  k  k  k  k  k k k k k k k k k  k  k ★ ★ ★ ★  ★ ★  ★ ★ ★ ★ ★ ★ ★ ★ ★  k k k k k k k k k k
KKGFSEADNV VSGELYIGGQ DHFYLETHCT IAIPKGEEGE MELFVSTQNA MKTQSFVAKM
LGVPANRIW RVKRMGGGFG GKETRSTWS TAVALAAYKT GRPVRCMLDR DEDMLITGGR
★ + ★ ★ ★  k  k k k k k k k k k k  ★ ★ ★ ★ ★ ★ ★  k  k  k k k k k k k k k  k k k k k k k k k k  k k k k k k k k k
LGVPVNRILV RVKRMGGGFG GKETRSTLVS VAVALAAYKT GHPVRCMLDR NEDMLITGGR
HPFLARYKVG FMKTGTWAL EVDHFSNVGN TQDLSQSIME RALFHMDNCY KIPNIRGTGR
★ k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k k k k k k k k k k  k k k k k k k k k k
HPFLARYKVG FMKTGTIVAL EVDHYSNAGN SRDLSHSIME RALFHMDNCY KIPNIRGTGR
LCKTNLPSNT AFRGFGGPQG MLIAECWMSE VAVTCGMPAE EVRRKNLYKE GDLTHFNQKL 
* * * * * *  * * *  * * * * * * * * *  * * *  * * * *  * * * * * *  * * *  + * *  * *  * * *  * * * * * * * *  *
LCKTNLSSNT AFRGFGGPQA LFIAENWMSE VAVTCGLPAE EVRWKNMYKE GDLTHFNQRL
EGFTLPRCWE ECLASSQYHA RKSEVDKFNK ENCWKKRGLC IIPTKFGISF TVPFLNQAGA
★ ★ ★  ★ ★ ★ ★  ★ ★ ★  ★ ★ ★ ★  k  k k k k k k k k k k  k k k k k k k k k k  k k k k k k k k k k  k k k k k k k k k k
EGFSVPRCWD ECLKSSQYYA RKSEVDKFNK ENCWKKRGLC IIPTKFGISF TVPFLNQAGA
LLHVYTDGSV LLTHGGTEMG QGLHTKMVQV ASRALKIPTS KIYISETSTN TVPNTSPTAA
★ k k k k k k k k  k  k  k  k  k  k  k  k  k k k k k k k k k k  k  k  k  k  k  k  k  k  k k k k k k k k k k  k  k  k  k  k  k  k  k  k
LIHVYTDGSV LVSHGGTEMG QGLHTKMVQV ASKALKIPIS KIYISETSTN TVPNSSPTAA
SVSADLNGQA VYAACQTILK RLEPYKKKNP SGSWEDWVTA AYMDTVSLSA TGFYRTPNLG
k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k  k ★ ★ ★ ★  k k k k k k k k k k
SVSTDIYGQA VYEACQTILK RLEPFKKKNP DGSWEDWVMA AYQDRVSLST TGFYRTPNLG
YSFETNSGNR FHYFSYGVAC SEVEIDCLTG DHKNLRTDIV MDVGSSLNPA IDIGQVEGAF
k k k k k k k k k  k  k  k  k  k  k  k  k  k  k k k k k k k k k k  k k k k k k k k k k  k k k k k k k k k k  k k k k k k k k k k
YSFETNSGNA FHYFTYGVAC SEVEIDCLTG DHKNLRTDIV MDVGSSLNPA IDIGQVEGAF
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VQGLGLFTLE ELHYSPEGSL HTRGPSTYKI PAFGSIPIEF RVSLLRDCPN KKAIYASKAV
k k k k k k k k k k  k k k k k k k k k k  k k k k k k k k k k  k  k  k  k  k  k  k ★ ★  k k k k k k k k k k  k k k k k k k k k k
VQGLGLFTLE
GEPPLFLAAS
k  k  k  k  k  k  k ★ +
GEPPLFLGAS
GVPENCKPWS
k  k  k  k  k  k  k  k
GAPGNCKPWS
ELHYSPEGSL HTRGPSTYKI PAFGSIPTEF RVSLLRDCPN KKAIYASKAV
IFFAIKDAIR AARAQHTGNN VKELFRLDSP ATPEKIRNAC VDKFTTLCVT
k k k k k k k k k  k  k  k  k  k  k  k  k  k  k k k k k k k k k  k k k k k k k k k k  k k k k k k k k k k




12.2 Sequence alignment of AOR and HLXOR.
AOR (Thoenes e t a l 1994); top sequence 
HLXOR (Ichida etal., 1993); bottom sequence
..MIQKVITV NG...IEQNL FVDAEALLSD VLRQQLGLTG VKVGCEQGQC GACSVI___
★ ★ ★ ★  k  k ★ ★  ★ k  k  k  k  k  k  k  k  k  k  k  k  k  k  k
MTADKLVFFV NGRKWEKN. .ADPETTLLA YLRRKLGLSG TKLGCGEGGC GACTVMLSKY
. . L D G K W R ........ ACVT KMKRVADGAQ ITTIEGVGQP EN. LHPLQKA WVLHGGAQCG
★ ★ ★ ★ k  k  k  k  k  k  k  k  k  k  k  k  k  k  k
DRLQNKIVHF SANACLAPIC SLHHVA  VTTVEGIGST KTRLHPVQER IAKSHGSQCG
FCSPGFIVSA KGLLDTNADP SREDVRDWFQ KHRNACRCTG YKPLVDAVM............
★ ★ ★ ★ ★  k k k k k k k k
FCTPGIVMSM YTLLRNQPEP TMEEIENAFQ G..NLCRCTG YRPILQGFRT FARDGGCCGG
.DAAAVIN GKK, 
★ ★ ★
DGNNPNCCMN QKKDHSVSHS PSLFKPEEFT PLDPTQEPIF PPELLRLKDT PRKQLRFERE
P ETDLEFKM. ★ ★ ★
RVTWIQASTL KELLDLKAQH PDAKLWGNT EIGIEMKFKN MLFPMIVCPA WIPELNSVEH
PADGRIWGSK YP.........................................................
*  *  *  *
GPDGISFGAA CPLSIVEKTL VDAVAKLPAQ KTEVFRGVLE QLRWFAGKQV KSVASVGGNI
ITASPISDLN PVFMASGAKL TLVSRGTRRT VQMDHTFFPG YRKTLLSPEE ILLSIEIPYS
................RPTAVA KVTGTL.........................................
*  *  * * *
REGEYFSAFK QASRREDDIA KVTSGMRVLF KPGTTEVQEL ALCYGGMANR TISALKTTQR 
............. DYGADLG. .LKMPAGT......................................
★ ★ ★ k  k
QLSKLWKEEL LQDVCAGLAE ELHLPPDAPG GMVDFRCTLT LSFFFKFYLT VLQKLGQENL
EDKCGKLDPT FASATLLFQK DPPADVQLFQ EVPKGQSEED MVGRPLPHLA ADMQASGEAV
191
.............LHLAMVQAK
★ *  *
YCDDIPRYEN ELSLRLVTST
FPTNKGDGWD RPILCDEKVF ★ ★ ★
......... D ETVFAKDKVT
AAEDAIEIHP GTPNVYFEQP ★ ★ ★ ★ ★
TIEDAIK...... NNSFYGPE
Y.MGDDGKCY IHSKSIGVHL ★ ★
VPKGEAGEME LFVSTQNTMK 
VAVAAMATGR PVHLRYNYQQ





★ ★ ★ ★ ★ ★  ★ k  k
VTCGMPAEEV RRKNLYKEGD 
TATHKKGVGI SIGVYGSAWT





•k k  k
PYKKKKPSGS WEDWVTAAYM 
TVTVATGRPP WTALTLMADL
★ k  k
EIDCLTGDHK NLRTDIVMDV
A G ..... FPF IKQIPDKLDI★ ★ ★ ★
RGPSTYKIPA FGSIPIEFRV
....... TGV RIYRL..PAY
* *  * *
RAQHTGNNVK ELFRLDSPAT
VSHANIKGID TSEALTMPGV
★ ★ k  k  k  k  k  k  k  k  k  k
RAHAKIKSID TSEAKKVPGF
QYGDCIALVC ADSEANARAA★ ★ ★ ★ ★ ★
CVGHIIGAW ADTPEHTQRA 
I . VKGEDTGP I FASADVTVE
★ k  k  k
LKIEKGDLKK GFSEADNWS
HLYMIAPGVG LEPDQLVLVA ★ ★
TQSFVAKMLG VPANRIWRV
QQQYTGKRSP WEMNVKFAAK ★ ★ ★ ★ ★
DMLITGGRHP FLARYKVGFM 
PNIRGLGRTV ATNHVWGSAF
k  k  k  k  k  k  k  k  k  k  k
PNIRGTGRLC KTNLPSNTAF 
TNPTGQEPEV FSLPDMIDQL











★ ★ ★ k  k  k  k
GSSLNPAIDI GQVEGAFVQG 
VYV.NHPRPD GPFGASGVGE





★ ★ ★  k  k  k  k  k
VCFISADDVP GSN.ITGICN
AEKVKVDLEE LPAYMSGPAA 
* ** ** **
AQGVKITYEE LPAII....
GDFYVGRQPH MPIEPDVAFA





★ ★ ★ k  k  k  k
KTGTWALEV DHFSNVGNTQ 
RGYGAPQSMF ASECLMDMLA







*  *  *  *  *  *  *
ADLNGQAVYA ACQTILKRLE 
VTGLGKPFW YMYGVFMAEV









12.3 Sequence alignment of HMXOR and HLXOR.
HMXOR (Briggs & Pearson, unpublished data); top sequence 
HLXOR (Ichida etal., 1993); bottom sequence
MTADKLVFFV NGRKWEKNA DPETTLLAYL RRKLGLSGTK LGCGEGGCGA CTVMLSKYDR
LQNKIVHFSA NACLAPICSL HHVAVTTVEG IGSTKTRLHP VQERIAKSHG SQCGFCTPGI
VMSMYTLLRN QPEPTMEEIE NAFQGNLCRC TGYRPILQGF RTFARDGGCC GGDGNNPNCC
TPLDPTQEP IFPPELLRLK DTPRKQLRFE GERVTWIQAS
A A A A A A A A A  A A A A A A A A A A  A A A A A A A A A A  A A A A A A A A A
MNQKKDHSVS HSPSLFKPEE FTPLDPTQEP IFPPELLRLK DTPRKQLRFE RERVTWIQAS
TLKELLDLKA QHPDAKLWG NTEIGIEMKF KNMLFPMIVC PAWIPELNSV EHGPDGISFG
A A A A A A A A A A  A A A A A A A A A A  A A A A A A A A A A  A A A A A A A A A A  A A A A A A A A A A  A A A A A A A A A A
TLKELLDLKA QHPDAKLWG NTEIGIEMKF KNMLFPMIVC PAWIPELNSV EHGPDGISFG
AACPLSIVEK TLVDAVAKLP AQKTEVFRGV LEQLRWFAGK QVKSVASVGG NIITASPISD
A A A A A A A A A A  A A A A A A A A A A  A A A A A A A A A A  A A A A A A A A A A  A A A A A A A A A A  A A A A A A A A A A
AACPLSIVEK TLVDAVAKLP AQKTEVFRGV LEQLRWFAGK QVKSVASVGG NIITASPISD
LNPVFMASGA KLTLVSRGTR RTVQMDHTFF PGYRKTLLSP EEILLSIEIP YSREGEYFSA
A A A A A A A A A A  A A A A A A A A A A  A A A A A A A A A A  A A A A A A A A A A  A A A A A A A A A A  A A A A A A A A A A
LNPVFMASGA KLTLVSRGTR RTVQMDHTFF PGYRKTLLSP EEILLSIEIP YSREGEYFSA
FKQASRREDD IAKVTSGMRV LFKPGTTEVQ ELALCYGGMA NRTISALKTT QRQLSKLWKE
A A A A A A A A A A  A A A A A A A A A A  A A A A A A A A A A  A A A A A A A A A A  A A A A A A A A A A  A A A A A A A A A A
FKQASRREDD IAKVTSGMRV LFKPGTTEVQ ELALCYGGMA NRTISALKTT QRQLSKLWKE
ELLQDVCAGL AEELHLPPDA PGGMVDFRCT LTLSFFFKFY LXVXXKLGQE NLEDKCGKLD
A A A A A A A A A A  A A A A A A A A A A .  A A A A A A A A A A  A A A A A A A A A A  A  A  A A A A A  A A A A A A A A A A
ELLQDVCAGL AEELHLPPDA PGGMVDFRCT LTLSFFFKFY LTVLQKLGQE NLEDKCGKLD
PTFASATLLF QKDPPADVQL FQEVPKGQSE EDMVGRPLPH LAADMQASGE AVYCDDIPRY
A A A A A A A A A A  A A A A A A A A A A  A A A A A A A A A A  A A A A A A A A A A  A A A A A A A A A A  A A A A A A A A A A
PTFASATLLF QKDPPADVQL FQEVPKGQSE EDMVGRPLPH LAADMQASGE AVYCDDIPRY
ENELSLRLVT STRAHAKIKS IDTSEAKKVP GFVCFISADD VPGSNITGIC NDETVFAKDK
A A A A A A A A A A  A A A A A A A A A A  A A A A A A A A A A  A A A A A A A A A A  A A A A A A A A A A  A A A A A A A A A A
ENELSLRLVT STRAHAKIKS IDTSEAKKVP GFVCFISADD VPGSNITGIC NDETVFAKDK
193
VTCVGHIIGA WADTPEHTQ RAAQGVKITY EELPAIITIE DAIKNNSFYG PELKIEKGDL★★★★★★★★★★ ★★★★★★★★★★ ★★★★★★★★★★
VTCVGHIIGA WADTPEHTQ RAAQGVKITY EELPAIITIE DAIKNNSFYG PELKIEKGDL
KKGFSEADNV VSGEIYIGGQ EHFYLETHCT IAVPKGEAGE MELFVSTQNT MKTQSFVAKM
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *
KKGFSEADNV VSGEIYIGGQ EHFYLETHCT IAVPKGEAGE MELFVSTQNT MKTQSFVAKM
LGVPANRIW RVKRMGGGFG GKETRSTWS TAVALAAYKT GRPVRCMLDR DEDMLITGGR★ ★★★★★★★★★ ★★★★★★★★★★ ★★★★★★★★★★ ★★★★★★★★★★ ★★★★★★★★★★
LGVPANRIW RVKRMGGGFG GKETRSTWS TAVALAAYKT GRPVRCMLDR DEDMLITGGR
HPFLARYKVG FMKTGTWAL EVDHFSNVGN TQDLSQSIME RALFHMDNCY KIPNIRGTGR
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *
HPFLARYKVG FMKTGTWAL EVDHFSNVGN TQDLSQSIME RALFHMDNCY KIPNIRGTGR
LCKTNLPSNT AFRGFGGPQG MLIAECWMSE VAVTCGMPAE EVRRKNLYKE GDLTHFNQKL★ ★★★★★★★★★ ★★★★★★★★★★ ★★★★★★★★★★ ★★★★★★★★★★
LCKTNLPSNT AFRGFGGPQG MLIAECWMSE VAVTCGMPAE EVRRKNLYKE GDLTHFNQKL
EGFTLPRCWE ECLASSQYHA RKSEVDKFNK ENCWKKRGLC IIPTKFGISF TVPFLNQAGA
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *
EGFTLPRCWE ECLASSQYHA RKSEVDKFNK ENCWKKRGLC IIPTKFGISF TVPFLNQAGA
LLHVYTDGSV LLTHGGTEMG QGLHTKMVQV ASRALKIPTS KIYISETSTN TVPNTSPTAA★★★★★★★★★★ ★★★★★★★★★★ ★★★★★★★★★★ ★★★★★★★★★★ ★★★★★★★★★★
LLHVYTDGSV LLTHGGTEMG QGLHTKMVQV ASRALKIPTS KIYISETSTN TVPNTSPTAA
SVSADLNGQA VYAACQTILK RLEPYKKKNP SGSWEDWVTA AYMDTVSLSA TGFYRTPNLG 
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *
SVSADLNGQA VYAACQTILK RLEPYKKKNP SGSWEDWVTA AYMDTVSLSA TGFYRTPNLG
YSFETNSGXP FHYFSYGVAC SEVEIDCLTG DHKNLRTDIV MDVGSSLNPA IDIGQVEGAF 
* * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *
YSFETNSGNR FHYFSYGVAC SEVEIDCLTG DHKNLRTDIV MDVGSSLNPA IDIGQVEGAF
VQGLGLFTLE ELHYSPEGSL HTRGPSTYKI PAFGSIPIEF RVSLLRDCPN KKAIYASKAV 
VQGLGLFTLE ELHYSPEGSL HTRGPSTYKI PAFGSIPIEF RVSLLRDCPN KKAIYASKAV
GEPPLFLAAS IFFAIKDAIR AARAQHTGNN VKELFRLDSP ATPEKIRNAC VDKFTTLCVT 
* * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *  * * * * * * * * * *
GEPPLFLAAS IFFAIKDAIR AARAQHTGNN VKELFRLDSP ATPEKIRNAC VDKFTTLCVT
GVPENXKPXL XXR 
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